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ABSTRACT 
Luke Edgar Roode: Sub-tumor distribution of PRINT nanoparticles and its application for nucleic acid 
delivery 
(Under the direction Ian Davis and Joseph DeSimone) 
 
 Nanoparticle accumulation is typically measured at the organ level. However, much basic in vitro 
and in vivo research points to differences in nanoparticle internalization and interaction among cell types. 
This is a particularly significant point when considering solid tumor drug delivery with nanoparticles where 
there is a significant interplay between the pathophysiology and physical forces present within the tumor, 
the nanoparticle itself, and the milieu of cell types present.  
 Unlike other nanoparticle fabrication systems, PRINT affords the exquisite ability to control size 
and shape of a given nanoparticle. Particles fabricated with this method are highly uniform, allowing for 
easy control and dissection of the interplay between nanoparticle properties and resulting effects. 
 Herein we describe an approach to examining the distribution of particles within the tumor. This 
approach accounts for 98.6% of all live cells that were dissociated from the tumor. Analysis of the particle 
association of the sub-populations present reveals that the nanoparticle dose administered shows dose-
independent cancer cell association at high doses using 80x320nm PRINT hydrogel nanoparticles. 
Moreover, this maximal association seen with this approach is roughly 7%. Notably, other immune cells 
like macrophages and neutrophils show significant association with particles. Quantification of the mean 
fluorescence intensity of particle-positive cells reveals that macrophages associate with significantly more 
particles per cell than any other cell type, perhaps suggesting that macrophages may be a significant 
target of nanoparticles within the tumor. Overall, however, the data shows that cancer cells are still the 
main cell type of accumulation due to the fact that in this model, macrophages make up roughly 1% of the 
tumor.  
 In vivo imaging using two photon microscopy supports the flow cytometry data, with host cells 
showing the brightest fluorescence and Td Tomato-expressing cells showing low-level fluorescence. 
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Normal mouse dermis shows little diffusion of particles outside the normal vasculature suggesting that the 
vasculature surrounding the tumor is uniquely permeable to nanoparticles like as in the EPR effect. 
Other nanoparticle factors like size and route of administration were similarly examined. Smaller 
nanoparticle size seemed to play a significant role in increasing cancer cell association as well as 
increasing the accumulation of particles to cancer cells. When administering particles intratumorally, 
cancer cell association was increased along with significant increases in the mean fluorescence intensity.  
 Combined, these results suggest a need for analysis of particle distribution and association at the 
cellular level. 
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PREFACE  
 I want to implore the readers of this dissertation that only by examining problems with 
complimentary techniques and with an open mind can one fully comprehend the complex interactions 
between nanomaterials and biological systems. The more clearly understood those aspects are, the 
closer the field becomes to unleashing the power of nanomedicine and avoiding clinical failure. 
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CHAPTER I: INTRODUCTION TO NUCLEIC ACID DRUG DELIVERY AND FLOW CYTOMETRY 
 
1.1 Nucleic acids in and gene therapy 
 1.11 Nucleic acids 
 Cells are a complex mixture of macromolecules and chemicals that must all work in synchronous 
harmony to allow for the cell to survive and thrive. This is not done in isolation, but as part of a 
surrounding environment. Mammalian cells must be capable of creating new copies of themselves during 
mitosis, as well as adapting to external stimuli from this environment. Therefore, an instruction set must 
be contained within the cell’s nucleus to provide the means and guidelines to do so. Nucleic acids are the 
chemical building blocks for the cell’s instruction set. This instruction set is made of 5 types of nucleic 
acids: adenosine, cytosine, guanine, thymine, and uracil, which form a polymeric chain of nucleotides 
linked by phosphodiester bonds. Two forms of nucleic acids exist: DNA and RNA, with the difference 
being that a polynucleotide structure of DNA does not contain uracil, while RNA does not contain thymine. 
DNA is conventionally double-stranded in nature and with the discovery of the structure of DNA in 1953 
by Watson and Crick[1], it was determined to form an alpha helix. This allows adenosine-thymine, or in 
the case of RNA adenosine-uracil, and cytosine-guanine base pairing between the strands due to 
hydrogen bonding between the pairs. DNA plays a critical role in mammalian cells by acting as an 
information storage unit due to its superior stability as compared to RNA. Due to the instability of RNA, 
the cell has evolved to use it as a single-stranded messenger. The “Central Dogma” asserts that DNA is 
transcribed into RNA. This ssRNA then moves from the nucleus of the cell into the cytoplasm. It is here 
where the cell’s ribosomes read or translate every 3 bases, termed a codon, and uses tRNAs to connect 
each amino acid together to form polypeptides, proteins, and other biofunctional molecules. These 
biofunctional molecules perform specific roles as receptors to sense the external environment, signaling 
proteins to transmit those sensations, and enzymes to convert chemicals to one form to another.  
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 1.12 RNAi 
  Discovered in 1998 and being deemed Nobel prize worthy in 2006[2], RNAi is thought to be a 
holdover from early in evolution as a response to foreign nucleic acid entry into mammalian cells. Where 
DNA and RNA work to express genes and create macromolecules, it was found that dsRNA could prompt 
the opposite response by decreasing the expression level of a gene. This was demonstrated to be a 
sequence-specific mechanism, with the specificity coming from nucleotides 3-17 of the 5’ to 3’ guide 
strand. It is suggested that even one nucleotide difference may abolish siRNA activity, though specific 
design parameters are not well understood[3]. The dsRNA is clipped by Dicer into 22nt strands with a 2nt 
overhang at each 3’ end.  This guide strand is unwound from its complementary strand and loaded into 
the RISC complex. Ago2 then cleaves the passenger RNA strand, leaving only the guide strand, and by 
that action activates the RISC complex. This loaded guide strand in an activated RISC complex then finds 
a complimentary mRNA strand to base pair with, which is then cleaved by the RISC complex resulting in 
a decrease in mRNA levels and consequently, protein levels. The RNAi phenomenon works not only for 
foreign RNA, but also is used endogenously by the cell as a way to regulate translation of proteins via 
mRNA levels. When DNA is being transcribed in the nucleus, hairpins in the RNA sequence can be 
formed by shRNAs or miRNAs and recognized by Dicer or Drosha and processed like an siRNA, resulting 
in cleavage of the target mRNA[4,5].  
 An alternative to RNAi gene knockdown is a similar phenomenon seen with antisense 
oligonucleotides, first described in 1977[6]. Typically, this is ssRNA or ssDNA and is of a complimentary 
sequence to the target sequence. Upon reaching the cytoplasm, Watson-Crick base-pairing allows for 
binding between the antisense oligo and the target mRNA. Then, the mRNA is either cleaved by RNAse 
H or the oligo acts as a steric blocker and prevents translation of the mRNA[7-9].  
 1.13 Nucleic Acid therapies 
  With the ability to increase or decrease the levels of genes seemingly by just adding different 
types of nucleic acids to cells, nucleic acids have the promise of solving many of man’s heretofore 
difficult-to-treat diseases. The simplest of these would be the monogenic diseases, where one gene or 
one certain factor is missing. Replacement or inhibition of a single gene or factor corrects the defect and 
cures the disease. Well-characterized examples of this are hemophilia, muscular dystrophy, cystic fibrosis 
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and alpha-1-antitrypsin[10,11]. In each of these diseases a single gene: factor VIII, IX, or XI, dystrophin, 
CFTR, or alpha-1-antitrypsin respectively, are mutated so as to be non-functional.  Clinical trials using 
various nucleic acid delivery approaches have been described in the literature. On the other hand, 
polygenic diseases such as cancer, type I diabetes, multiple sclerosis, asthma, celiac disease, and heart 
disease, are not the result of a single causative agent. Rather, these are a composite of the influence of 
genetics and environment (diet, exposure, etc.) and as such are more difficult to precisely target. 
Nevertheless, much research has been done on these diseases using nucleic acids. 
 1.14 Barriers to nucleic acid therapy in vivo 
 However, some basic biology and properties of nucleic acids limit their application in non-culture 
systems (i.e. animals). Firstly, nucleic acids are by their nature very hydrophilic polymers. They contain a 
sugar residue along with hydrogen-bonding groups and ionizable anionic phosphate groups connecting 
each nucleoside to one another. This makes nucleic acids unable to penetrate the lipid bilayer found on 
mammalian cells. In vitro this can be overcome by complexation with cationic polymers or lipids to form 
poly or lipoplexes, however these complexes are not stable when diluted upon administration. Many 
additional barriers exist for nucleic acid delivery in vivo. Upon systemic administration, nucleic acids 
encounter significant amounts of nucleases in the bloodstream. Thus, the pharmacokinetic half-life of 
injected nucleic acids is extremely short at less than 17 minutes[12]. Since this is an enzymatic 
degradation reaction, chemical modification of the nucleic acid, particularly siRNA, can be taken to inhibit 
the degradation. These include 2’-O-methyl or 2’-fluoro modifications of the sugar base or replacement of 
the phosphodiester with phosphothioate linkers. Phosphorodiamidate, LNA, or UNA modifications can 
also be used to enhance the stability of nucleic acids[13,14].  Beyond the plasma stability issue, the next 
barrier encountered is the endothelial cell lining of blood vessels. Nucleic acids must either transverse 
these cells or pass between them through the tight junctions linking them together. Due to the hydrophilic 
nature of the nucleic acids mentioned previously, transcellular pathways are inefficient and thus the 
nucleic acids must pass paracellularly. Once to the cells of interest, once again the cell membrane 
presents a challenge by not allowing passive diffusion of the nucleic acid. Assuming our nucleic acid is 
fortunate enough to be internalized by the cell by an endocytotic mechanism, the endosome itself now 
presents a challenge. Endosomes are slowly acidified by a proton ATPase going from a pH of 7.4 to 6-
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6.5, and with further acidification to a pH of 4.5-5. At this later stage the vesicle is referred to as a 
lysosome and the low pH environment there destroys most biological components due to the high acid 
content. Therefore, to avoid acidic destruction of our nucleic acid, it must escape the endosome. There 
are a variety of means to achieve endosomal escape, however, alone our nucleic acid does not have the 
means to do so. Once free, the nucleic acid can either be active in the cytosol as in the case of siRNA or 
mRNA or encounter the additional hurdle of nuclear trafficking and import as in the case of DNA. It should 
also be noted that nucleic acids have the ability to stimulate the immune system via activation of TLR 
receptors[15]. This fact can be somewhat controlled by the sequence of the siRNA, but can be of benefit 
or a hindrance depending on the downstream application. Hence, protection and delivery of nucleic acids 
is the key challenge in translating success in culture systems to animal systems.  
 1.15 Viral vectors for gene therapy 
 One way of addressing the delivery challenges is to package nucleic acids into viruses. Viruses 
have evolved to solve many of the delivery challenges presented above. Viruses are a kind of self-
assembled biological nanoparticle, with sizes ranging from 20nm to a few hundred nm[16-18]. Depending 
on the type, viruses protect the nucleic acid cargo with either a protein capsid and/or a lipid bilayer known 
as an envelope. Viruses have evolved to transcytose the endothelial cell lining, reaching cells. Once 
there, there are usually multiple receptors and co-receptors that bind to a given virus, allowing for efficient 
internalization of the virus into the cell. In the endosome, viruses have evolved elegant escape 
mechanisms, ranging from lipases to conformational switches of the capsid proteins to expose cationic 
charges. Whatever the mechanism, efficient endosomal escape of the virus allows for either depositing its 
nucleic acid cargo in the cytoplasm or trafficking to the nucleus. However, three main drawbacks to viral 
vectors exist. First, viral vectors always require nucleic acids trafficking to the nucleus resulting in slower 
kinetics of gene expression or knockdown. Second, viruses are not well suited to mass production. Being 
a biological entity, this requires humans to manipulate cells into creating, assembling, and packaging the 
virus. While these requirements are not insurmountable, culturing cells and purifying the virus from them 
can be very time consuming and labor-intensive processes not amenable to high throughput scale-up. 
Third and most importantly, naturally present immunity to the viruses and/or the ability to elicit high 
inflammatory responses and immune cell activation after administration requires that careful monitoring 
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be performed for signs of toxicity after administration of viral vectors[19]. These drawbacks 
notwithstanding, viral vectors have entered phase I and phase II trials for both therapeutic and vaccine 
applications[20,21]. These trials demonstrate that viral vectors can be tolerated, however, as these 
reports note, significant immune response to the virus is observed[22].  
 1.16 Non-viral methods for gene therapy  
 Non-viral delivery systems possess the advantages of low immunogenicity, low cost and exquisite 
control over the composition. These come in a variety of forms and materials. These forms can be a 
mode of administration like the gene gun or hydrodynamic delivery or a physical carrier/protective coating 
such as inorganic metals, lipoplexes, polyplexes, cell penetrating peptides, or polymeric nanoparticles.  
 Hydrodynamic delivery of nucleic acids is a non-viral concept first reported in 1999[23]. This 
concept involves injecting a large volume of fluid in a short time span. This sudden rise in blood fluid 
volume in a sense stretches the endothelial cell barrier, creating large fenestrations. This allows naked 
nucleic acids or carriers in this solution to circumvent the blood and endothelial barriers. When 
systemically performed, most nucleic acid concentrates in the hepatocytes of the liver. However, this 
method is optimal at 1mL of solution per gram of animal weight; an easy enough volume to work with in a 
mouse, but not practical for a human. This is especially true since it has many dangerous side effects like 
high blood pressure, low heart rate, and possibly death. One could possibly use this technique in isolated 
limbs. The gene gun is another form of physical delivery that has been used successfully for plasmid DNA 
vaccine applications. The gene gun was originally shown to work by coating metallic particles with 
plasmid DNA and then propelling them into an object, specifically the skin of an animal. The large force 
from the shot helps the metal-DNA particles penetrate the outer layers of skin to reach the dermis. 
Electroporation is another physical method of gene delivery that uses a voltage potential to force the lipid 
molecules in the cell membrane to shift position slightly, creating nm-sized pores for large 
macromolecules like nucleic acids to enter the cell. However, this can lead to a large amount of cell death 
and damage. Ultrasound and applied magnetic fields represent gentler methods to generate reversible 
pores in cell membranes for gene delivery[24].  
 Beyond specific methods, nucleic acid carriers come in a few different forms defined by the 
mechanism by which they interact with the nucleic acid. Due to the many negative charges present on the 
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phosphodiester backbone of nucleic acids, complexes with cationic molecules are easily formed. This 
kind of complex based on electrostatic interactions is termed a polyplex or lipoplex, depending on 
whether the nucleic acid binding partner is a polymer or a lipid. The N:P ratio, that is the molar amount of 
cationic nitrogen groups to phosphate groups present on the nucleic acid, helps determine how tightly the 
poly/lipoplex binds the nucleic acid. Common lipids for this include DOTAP, PEI, and DOPC. The cationic 
nature of the lipids is both a blessing and curse. A blessing in the sense that this allows for tight binding of 
the lipid to the nucleic acid, affording protection and perhaps some compaction of the nucleic acid. A 
curse in the sense that enhanced binding to the nucleic acid also hinders release of the nucleic acid, 
resulting in a lack of available nucleic acid to elicit an effect. Moreover, the cationic groups can interact 
with the cell membrane, causing toxicity. PEI is notable for its toxicity, whereas DOTAP and DOPC are 
much less toxic[25-30]. Common polymers for the formation of polyplexes include chitosan[31], 
cyclodextrins[32,33], or dendrimers[34,35]. Chitosan and cyclodextrin are naturally-occurring 
polysaccharides that are cationic, whereas a dendrimer is a highly branched, symmetrical, synthetic 
polymer. These polymers are all show relatively low toxicity, however they are variable in their ability to 
create a successful delivery vehicle. Chitosan has been shown to have poor endosomal escape of the 
nucleic acid, but a cyclodextrin-based polyplex haven been advanced to clinical trials where it showed the 
first RNAi effects from systemic administration in humans[36]. An alternative to polymers and lipids are 
cell penetrating peptides. These are typically 10-30 amino acids in length with a stretch of cationic amino 
acids like lysine and arginine. The first reported discovery was the HIV-1 TAT peptide that demonstrated 
cell penetration and activation of the HIV-1 promoter. CPPs can either be attached to a nucleic acid 
chemically or form a complex directly. Both chemical attachment and electrostatic complexation have 
been shown to be effective in cell culture systems[37-42]. In addition to electrostatic interactions, various 
polymers have been used to entrap siRNA within them. For example, PLGA can effectively entrap siRNA 
and be used for successful pre-clinical gene therapy[43-46]. Inorganic elements can also be used to 
directly conjugate nucleic acids to a delivery vehicle. Collodial gold has been used by Mirkin and other to 
demonstrate successful nucleic acid delivery[47]. Other heavy-metal elements such as those contained in 
quantum dots have demonstrated successful delivery in culture systems although concerns remain about 
their toxicity, similar to the literature surrounding of carbon nanotubes. LCP particles use calcium to form 
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complexes with nucleic acids, which can then be coated with lipids. This recent development in particle 
composition has shown promising pre-clinical results for the delivery of nucleic acids[48,49]. In whatever 
form nucleic acids are interacting with a material, these mixtures generally form what is known as 
nanoparticles.  
1.2 Nanoparticles 
 1.21 Basic information and fabrication methods 
 Nanoparticles can range in size from 1-10,000nm, with at least one dimension <100nm. This puts 
these objects in a size range similar to bacteria and viruses. These particles are invisible to the naked 
eye, but can be viewed with the aid of light or electron microscopes. Nanoparticle carriers can be made 
by various methods, but generally fall into two categories of fabrication: bottom-up and top-down. Bottom-
up approaches for nanoparticle fabrication typically rely on emulsions or inverse microemulsions to direct 
self-assembly of spherical particles, requiring energy to create particles in the 10-100nm range[50]. 
These types of approaches can be used with many different materials, but also produce significant 
variation in particle size. In contrast, top-down fabrication approaches use patterns and templates to 
confer the advantage of uniform size[51]. These fabrication techniques rely on photolithography or imprint 
lithography, common techniques in the microelectronics industry. Photolithography involves using lasers 
to etch a design or cavity into a given surface. The drawback to photolithography is that fabrication of 
nano-scale templates requires shorter and shorter wavelengths of light (e.g. 157nm F2 lasers) and thus 
become technically complex and expensive to operate at small particle dimensions. On the other hand, 
imprint lithography uses a mold containing cavities and a curable liquid to create objects on small size 
ranges. This approach should be more cost-effective as compared to photolithography, however, the 
small features created by this process are generally interconnected by “scum” layers. In the 
microelectronics industry, these scum layers would be dissolved with harsh chemicals or processes. 
Sensitive biological samples, however, would not survive such harsh treatment therefore making this 
approach impractical for creating nanoparticle carriers for biological cargo. 
 1.22 Particle Replication in Non-wetting Templates (PRINT) 
 PRINT is a nanofabrication technique similar to imprint lithography, using a patterned mold and 
curable liquids[52]. However, it has a decided advantage against other forms of imprint lithography. In the 
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PRINT process, the mold is made of PFPE. Due to the high fluorine content, these molds have roughly 
half as much surface energy as other common materials molds are made of such as PDMS (12 dynes 
cm-1 vs 20 dynes cm-1)[53].  Due to this property, this makes molds made of PFPE non-wetting and non-
swelling. This means that the curable materials will not stick to the non-cavity portions of the mold, 
thereby avoiding the “scum” problem inherent to conventional imprint lithography. The cavities can be 
filled through capillary action or melt filling, depending on the material used for fabricating the particles. 
Once filled, the mold can be laminated to a sacrificial harvesting layer. The harvesting layer is then 
dissolved, leaving free particles in solution. This approach allows for monodisperse nanoparticles, made 
in a scalable fashion, giving PRINT a decisive advantage over other forms of nanoparticle manufacture. 
Moreover, this process is amenable to sensitive biological cargoes such as protein and nucleic 
acids[52,54].  
 1.23 PRINT systems for siRNA delivery 
 The first reported use of nucleic acids in PRINT was using siRNA duplexes and the material 
PLGA[55]. PLGA is a co-polymer composed of lactide and glycolide. Both lactide and glycolide are 
considered GRAS by the FDA due to their use as excipients in numerous pharmaceutical products and 
the fact that they are components of the TCA cycle and would thus be broken down naturally by the body. 
The FDA accepted nature of a degradable particle is attractive when designing a particle delivery system 
for future translational use. When using a luciferase-expressing HeLa cell line, it was found that cationic 
lipid-coated 80x320nm PLGA particles had comparable IC50 knockdown values as lipofectamine, with 
minimal toxicity of the particles seen. Moreover, the loading of the particles was influenced by the 
molecular weight and lactide: glycolide ratio of the PLGA, with shorter, higher lactide-containing PLGA 
resulting in higher loading of siRNA.  
 A separate particle matrix was also tested for its ability to carry siRNA. This matrix was a 
hydrogel particle composed of hydroxy-PEG acrylate, PEG diacrylate to crosslink the acrylate monomers, 
and amino-ethylmethacrylate to provide a functional handle for amine surface chemistry. The acrylate 
groups are then photopolymerized to create a covalently crosslinked particle. Due to the covalent bonds 
present these particles show very slow degradation. This resistance to degradation gives the advantage 
of preventing premature release of the siRNA. At first, siRNA was simply complexed to the 200x200nm 
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particles via electrostatic interactions. However, in salt solutions and other biological fluids, significant 
siRNA release was observed. This release problem led to the creation of a conjugated siRNA approach 
where siRNA was conjugated to an acrylate group through a disulfide bond[56]. The thinking here was 
that the disulfide bond would be stable in biological fluids until entering the endosome. Upon entry into the 
endosome, the reducing environment in the endosome would cause release of the siRNA. Good in vitro 
knockdown in luciferase-expressing HeLa cells was observed with a maximum EC50 of 15.1nM. However, 
these particles were fabricated with 50wt% of AEM and showed significant toxicity. The amount of AEM 
contained in these particles could be reduced to 30wt% AEM without loss of knockdown efficiency. Lower 
amounts of AEM could be used, such as 20wt%, but the EC50 increased to 69.4nM. 
 In vivo results have not been published to date for either the PLGA or Hydrogel matrix, but are an 
area of active investigation.  
1.3 Nanomedicine in oncology 
 1.31 The EPR effect and circulation time 
Nanoparticle applications in oncology typically focus on systemic injection of particles for the treatment of 
solid tumors. The prevailing wisdom is that once tumors reach a critical size, the blood vessels originally 
supplying the tumor can no longer support all the cells present. Once some of the cells start to die, 
angiogenic factors such as VEGF are secreted[57]. This stimulates the formation of new blood vessels. 
However, proper blood vessel formation requires the correct balance of growth factors. Due to the 
imbalance of factors, the newly forming blood vessels seem to have large fenestrations present[58,59]. 
The size of these fenestrations is dependent upon the tumor type, location, and microenvironment, 
estimated to be between 200-2000nm[60,61]. And while there is residual lymphatic draining and a little 
neolymphangiogenesis, it is thought that the bulk of the tumor has an overall lack of lymphatic 
drainage[62]. This creates a situation where macromolecular species such as proteins, antibodies, and 
nanoparticles penetrate the endothelial barrier through the fenestrations, but are then trapped there by a 
lack of convective forces to carry it back to the bloodstream. This effect is dependent upon the size of the 
macromolecule as objects 4-5nm in hydrodynamic radius can diffuse easily back to circulation[63]. Thus, 
an object between 5nm and the size of the endothelial fenestrations can be effectively trapped between 
blood vessels and cancer cells. This so-called EPR effect, discovered by Matsumura & Maeda in the 
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1986, is the main justification for the application of nanomedicines for cancer drug delivery[64]. In their 
experiments, 51Cr was used to radiolabel 6 different proteins ranging in molecular weight from 12,000-
150,000. Due to the radiolabeling, the authors were able to track the blood pharmacokinetics and tissue 
accumulation of the proteins over time in outbred ddY mice bearing sarcoma 180 tumors on their backs. 
Albumin and IgG had very long half-lives of about 35 hours and also had the greatest amount of 
accumulation in tumors at around 7.5% of the injected dose. From the other proteins injected, a rough 
correlation between circulation time and accumulation was found. Hence, the EPR effect postulates that 
the longer a macromolecule can circulate, the greater accumulation within a tumor it will have. This 
reasoning has led to a focus on two things: increasing the circulation time of particles following systemic 
administration and thusly increasing the accumulation of nanoparticles in tumors.  
 It should be noted that while the EPR effect has seemingly been demonstrated in animal models, 
there is inconclusive evidence that the EPR effect exists in humans. During the evaluation of liposomal 
doxorubicin (Doxil), doxorubicin concentrations were measured in tumor biopsies directly or the tumors 
were imaged using radionuclide labeled liposomes. The general results were that in 3-7 days a 4-16-fold 
higher concentrations of doxorubicin or particle were seen in the tumor as compared to the blood[65,66]. 
This was postulated as evidence of the EPR effect, however, the half-life of doxorubicin and doxil are 
strikingly different at 10.5 vs 45.9 hours. This confounds the experiment and results in an unclear 
conclusion. Review of the available literature suggests that only sarcomas show a tumor: surrounding 
tissue/blood signal greater than 1, indicating preferential accumulation. Brain metastases, bone 
metastases, glioblastomas, breast, lung, and ovarian cancers show a ratio less than 1[65-70]. However, 
these are quantitated by a mixture of methodologies, all of them less optimal than the approaches that 
have been performed in pre-clinical studies (i.e. organ harvest and direct quantitation). There is also a 
lack of efficacy data to evaluate the relationship between accumulation and efficacy. Moreover, the 
majority of current clinical data is with liposomes, specifically Doxil. It is therefore unknown what effects 
particle properties like size, shape, or drug release kinetics may have on accumulation or therapeutic 
effect. It must also be noted that patients able to be enrolled in phase I clinical oncology studies are most 
likely refractory to standard of care therapy, usually various chemotherapies. These patients may 
represent a sub-set of difficult to treat patients or the environment of the tumor may have changed 
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substantially following treatment. It is therefore difficult to determine whether the animal models are of 
predictive value except by efficacious outcome and there is seemingly little predictive value of the clinical 
utility and outcome in humans when using the typical xenograft mouse model[71-73].  
 Circulation time of nanoparticles was thought to be a function of non-specific protein adsorption 
on the surface of the particle, leading to internalization by resident macrophages in the liver and spleen. 
However, recent work by Jones, et. al. used intravital microscopy to examine the circulation time of 
various PRINT Hydrogel particles[74]. In the course of this work, it was discovered that monocytes and 
neutrophils in the bloodstream are primarily responsible for circulating particle clearance. Moreover, the 
background strain of mice used also significantly influenced the resulting circulation time of the particles. 
It was found that more Th1-prone strains such as C57BL/6 and B10D2 had longer particle circulation time 
as compared to more Th2-prone strains such as BALB/c and DBA2. This was hypothesized to be due to 
differences in macrophage polarization, with Th1 biased towards M1 macropahges and Th2 biased 
towards M2 macropahges. M1 macrophages are thought to be more inflammatory and active in the 
destruction of pathogens, whereas M2 macrophages are thought to be more anti-inflammatory[75]. 
Paradoxically, M2 macrophages are also thought to have greater rates of endocytosis due to enhanced 
expression of scavenger and lectin receptors[76]. Previous work had implicated various receptors such as 
the scavenger receptor, Fc receptors, and complement, based on in vitro studies using cultured cell 
lines[77-79].   
 Particle internalization by cells of the MPS system can be discouraged by having the surface of 
the particle be hydrophyllic. This is most commonly accomplished by making “stealth” particles by the 
attachment of a PEG polymer on the surface of the particle (PEGylation). Quantification of the amount of 
PEGylation on particles needed to significantly extend circulation time has been shown to be 0.1 
PEG/nm2[80]. This quantification ensures that Rf/D > 1, where Rf is the Flory radius, and D is the distance 
between the PEG polymers attached at the particle surface. The Flory radius is calculated as Rf = 3/5*αn 
where α is the length of the monomer unit in angstroms (equal to 3.5 Å for PEG) and n is the number of 
repeat units of the monomer (equal to 50 for PEG of 2k MW). When Rf/D >1 it is thought that PEG is in a 
“brush” confirmation where each polymer chain is extended from the surface of the nanoparticle. This 
provides the benefit of inhibiting MPS cell internalization, thereby extending circulation time[81]. Maximal 
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benefits of a reduction in MPS cell internalization and extension of circulation time is seen at Rf/D >2, a 
state termed a “dense brush” of PEGylation[82]. When Rf/D <1, PEG is thought to adopt a “mushroom” 
conformation where the PEG is not extended, but collapsed to the surface of the particle. When this 
occurs, no benefit in preventing MPS internalization and circulation time extension time is seen[81]. A 
recent study by Yang et. al. demonstrated with in vitro assays for MPS cell uptake and circulation time 
screening by intravital microscopy that polystyrene particles required an Rf/D >2.8, or 1 PEG/nm2, to show 
any reduction in cell internalization and extension of circulation time[83]. Whether this discrepancy in the 
requirement for PEG density can be attributed to the particle size, particle matrix, or attachment 
chemistries is unclear.  
 1.32 The biodistribution of nanoparticles  
Upon systemic injection of nanoparticles, there are four possible routes for elimination. The first is 
filtration by the kidneys. This only applies for nanoparticles <20nm in size and does not seem to be 
affected by the type of material the particle is made of[84,85]. The second route of elimination is filtration 
by the lungs. Converse to the kidneys, the lungs will only entrap larger, micron-sized particles as the 
small blood vessels used to collect oxygen from the air are not large enough to allow free flow of larger 
particles. Unlike the kidney, aggregation of particles here leads directly to catastrophic event: 
asphyxiation of an animal. Thus, aggregation of particles and high accumulation in lung is a serious issue. 
The bloodstream represents a third possible route of elimination. Nanoparticle internalization by 
monocytes, neutrophils, dendritic cells, and other leukocytes present within the blood stream[74,86-88] 
represents a major factor in circulation time of the particles. Other cells present in the bloodstream, such 
as red blood cells and platelets may also play a role in interacting with the particles, but only serve as 
effectors to cause toxicity or uptake by the previously mentioned cell types. The fourth possible route of 
elimination is by resident phagocytic cells present within tissue. In practice, this refers to the specialized 
macrophage cells present in the liver, the Kupffer cells, and the high concentration of B cells present 
within the spleen[89,90].  
 Generally, the major organs of particle accumulation are the spleen and liver, usually with 20-
40% of the injected dose present in each organ[91-93]. This is thought to be due to particle internalization 
by the Kupffer cells of the liver and a combined cell/mechanical clearance by the spleen. This balance 
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somewhat shifts to favor splenic accumulation, depending on the circulation time of the particle with 
longer-circulating particles showing greater spleen accumulation[94]. All other organs generally contain 
only a small fraction (<5%) of the injected dose. Tumor accumulation of particles has ranged from 1-15%, 
depending on the particle size, material, deformability, stability, surface charge, degree of PEGylation, 
dose administered, and the animal model used.  
 1.33 Methods for measuring accumulation of particles in organs  
 Methods for calculating the percent injected dose can vary in the details, but fall into 3 main 
detection methods: radionuclides, metals & inductively coupled plasma mass spectrometry, and 
fluorescence. This is compounded by one of two main data collection methods: either whole body 
imaging or by individual organ collection.  
 Radionuclides come in a large variety of properties. The half-life of the radioactivity may be short 
like the 2 hours of 18F or longer such as 13 hours using 64Cu, 2.8 days using 111In, or 4.2 days like 124I. 
Some are best used for PET imaging such as 18F and 64Cu, whereas others offer economical benefits for 
the budget-conscious researcher like 111In.Various forms of radioactivity exist like alpha, beta, and 
gamma emissions and the specific radioactive particle measured is specific to the decay of each 
radionuclide. In any case, the main benefit of using of radionuclides is the extremely sensitive detection 
and quantitation limits possible when using radioactivity[95,96]. However, the obvious limitation of 
radionuclides is the extreme caution and hazard when using a silent killer such as radioactivity.  
 Inductively coupled plasma mass spectrometry creates droplets of a liquid solution and 
introduces it to argon plasma, heating with a plasma torch. By mixing the plasma with liquid droplets, this 
creates a gas that is consequently ionized. These ions can then be focused and analyzed on a mass 
spectrometer. In this way, elemental analysis on a sample can be performed. By using a standard curve it 
is possible to quantitate the actual amount present in a given sample. With a sensitivity in parts per trillion 
and a working range of 9 orders of magnitude, this technique can be easily and highly quantitative[97]. It 
is also much safer than using radionuclides. However, unlike radionuclides, it is only highly quantitative 
when using something with low background in biological samples such as rare metals. Often, this 
technique is used to quantitate the amount of Cu, Fe, Pt, or other rare metals[98]. Applying this technique 
in the context of nanoparticle distribution usually requires that the particle be loaded with a specific metal 
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or created entirely out of it[99]. Moreover, this is only useful in the context of harvesting individual organs 
and cannot be used for imaging.  
 Fluoresence on the other hand is a safe method that allows for detection of nanoparticles either 
with whole-animal imaging or individual organs. This comes from a chemical, a “fluorochrome”, that 
absorbs a particular wavelength or range of wavelengths of light. This wavelength excites an electron 
found in that fluorochrome to a higher energy state. Once the electron falls back to its ground state, the 
energy given off is in the form of photons. Depending on how large of a difference there is between the 
excited and ground state, this will determine the energy and thus, the wavelength of the photons given 
off. Fluorochromes exist across the entire UV, visible and near-IR electromagnetic spectrum. Near-IR 
dyes are exquisitely useful for whole-animal imaging because of the natural autofluorescence of biological 
tissue in the green and yellow/orange spectrums of visible light. This occurs because of various flavin and 
porphyrin chemicals found within the cells. In addition, elastin, collagen, and lipofuscin also add to 
autofluorescence found in tissues[100,101]. Each tissue will have its own particular amount of 
autofluorescence due to the slight variances in the amount of autofluorescent chemicals and proteins 
present[102]. This method is sensitive, though not nearly as sensitive as radionuclides or ICP-MS. 
However, this method is also amenable to sectioning and visualization of the tissue itself to examine 
microscopic architecture[103,104], giving it an advantage over the other two main forms of detection. 
1.4 Flow cytometry 
 Flow cytometry is essentially a way of analyzing a sample at the level of an individual cell. It 
requires the blending of fluidics, light/optics, photodetectors and filters, and computers to correlate and 
process the light-based signals into visually pleasing formats. In essence, single cells flow past a light 
source such as a laser, the cells are thus stimulated to scatter and emit light (fluorescence) which is 
captured by photodetectors/multipliers at various wavelengths determined by the optical filters. The 
beauty of this is that each cell may have a specific fluorescence pattern. With computers it is possible to 
record and organize each individual cell’s fluorescent pattern, allowing for complex analyses of cells to 
take place using fluorescent marking methods such as fluorescently-conjugated antibodies.  
 It is acknowledged that the first prototype was described in 1934 by Andrew Moldavan[105]. More 
or less, it was a microscope with a capillary tube across the light source such that cells were illuminated 
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as they passed through the light source. A photodector attached to where the eye piece of a microscope 
would normally be then captured the light. Some follow up work by Coulter, Kamentsky and Melamed, 
and others[106-109], provided a basis for which the modern cytometer design was implemented from the 
work of Fulwyler, Dittrich and Göhde, Van Dilla, and Herzenberg[110-112].  
 Due to the requirement for single cell suspensions, at first only blood cells were analyzed with this 
technique as there was no need for manipulation of the cells[113]. This has expanded from blood to 
tissue with the aid of enzymes and physical methods to dissociate the cells from the interconnected, 
complex mixture of cells that make up tissue, and other types of cells such as bacteria[114], sperm[115], 
and plankton[116]. In a sense, anything can be run on a flow cytometer so long as it meets the basic 
technical requirements that it can be run in a narrow stream of fluid and is between 1-30µm in size. 
However, those boundaries are being pushed as cytometers have been demonstrated to be capable of 
analyzing latex beads[117], cell nuclei[118], chromosomes[119], DNA fragments[120], viruses[121], and 
micron-sized nanoparticles[122]. These can be scanned at a rapid rate by the cytometer, approaching 
100-5,000 events per second. The limiting factor in analysis speed is ensuring that single cells are flowed 
past the light source. This is accomplished by either confining cells to a narrow, optically clear chamber or 
through the beam of a nozzle with a small hole. Due to the confined nature of this passage it is critical 
that large aggregates or chunks not be present in solution. Many a cytometer and experiment have been 
broken by something as simple as a clogged cytometer. Also, to prevent once individual cells from 
clogging, cytometers have evolved to injecting the cell suspension into the center of wide, quickly flowing 
stream (the sheath fluid). In a sense, hydrodynamic properties ensure this design creates the laminar flow 
seen by blood vessels where most objects are confined to the middle of the stream (hydrodynamic 
focusing). Due to these same hydrodynamic properties, the flow rate will directly impact how wide a 
stream the cells are confined to.  
 Cells naturally both scatter and emit light. In modern cytometers, lasers are used to stimulate 
cells due to the narrow, intense beams of light that lasers emit. Currently, these lasers are usually gas 
lasers such as argon ion, helium-neon, krypton ion or solid-state lasers such as a diode. Each laser has a 
specific wavelength of light that is emitted by the laser. This allows for specific stimulation of various 
chemicals or residues of certain proteins known as fluorochromes. Ideally a fluorochrome is only 
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stimulated at maximum intensity at precisely one wavelength. In reality, a fluorochrome is stimulated at 
different intensities over a range of wavelengths. This stimulation is represented by electrons from a 
molecule excited to a higher orbital. When the electrons fall back to a ground state, longer wavelength 
light is emitted. (e.g. stimulation with 488nm light may allow for emission of >500nm light) Similar to 
absorption, emission also occurs at different intensities over a range of wavelengths. 
 In modern cytometers, cells are passed through a 488nm laser and 488nm light is scattered in 
both a “forward” and “side” direction. “Forward” meaning along the path of the laser and “side” meaning 
orthogonal to the laser (along the path the cell is traveling). Collection of the “forward scatter” (FSC) light 
is colloquially taken as a reference to the volume or size of a cell passing through. In reality, it is a little 
more complex as it is a measure of the 3-dimensional angles at which light has been refracted by an 
object. Objects (cells) with a larger cross sectional area will give larger FSC values. However, a similarly 
large object with a refractory index similar to the medium the objects are in (e.g. dead cells) will give a 
seemingly smaller FSC. “Side scatter” (SSC) light will be refracted by irregularities or texture on the 
surface or in the cytoplasm of the cell, colloquially referred to as cell “granularity”. In this way, cell types 
and live/dead status can be differentiated with these measurements. For example, granulocytes with 
irregular nuclei will have higher SSC than lymphocytes and their spherical nuclei. The velocity of the cells 
through a cytometer can approach 5-50 m/s, meaning that cells will only spend roughly 0.2-4 µs in the 
laser beam. Since fluorochromes absorb and emit light on the nanoseconds time scale, basic division 
suggests that absorb and emit 100-1000 times while in the laser.   
 Fluorochromes, as discussed previously, require specific excitation laser and emit as specific 
wavelengths. Cells have natural fluorescence, termed “autofluorescence”. This can come from pyridine or 
flavin-type molecules present in mammalian cells or chlorophyll present in plant cells. Moreover, this can 
be worsened with the use of various cell fixatives such a formaldehyde, which crosslink proteins through 
amine groups particularly lysine residues. Beyond autofluorescence, most applications of cytometry seek 
to quantify or detect various markers, usually proteins. These markers can be on the surface or 
intracellular. Typically, an antibody, either directly conjugated to a fluorophore or not, is added to the cell 
suspension and incubated for some time, usually 30-60 minutes on ice. After that time, the cells are 
washed and if a directly conjugated antibody is not used, a secondary antibody that is directly conjugated 
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is used to detect the first antibody. For intracellular antigens, gentle detergents such as saponin are used 
to allow for antibody penetration into the cell without destroying the membrane.  
 However the fluorochromes are detected on or in a cell, the emission of these fluorochromes are 
detected in a similar manner as the SSC. While passing through a given laser, orthogonal emission of 
fluorochromes, like the scatter from SSC, are directed towards various dichroic mirrors. These mirrors 
reflect a given range of wavelengths of light and let all others pass through them. In this manner, a series 
of dichroic mirrors can serve to partition the emitted light. From there, filters specifically aligned with the 
light coming from the dichroic mirrors narrow the specific wavelengths of light further. After this process, 
the filtered light is detected by photomultiplier tubes (PMT). This example system contains only 1 laser, 
but more than 1 laser is ideal due to the plethora of fluorochromes that are available today and the 
various excitation wavelengths needed. For multiple lasers, the cells will pass by each laser individually, 
with the time between each laser on the µs time scale.  
 Practically speaking, a massless, chargeless photon of light strikes the photomultiplier tube. The 
photoelectric effect is then harnessed so that the photon creates a current by transferring its energy to the 
electrons in the PMT. The electrons move to a cathode thereby creating a current. This current is then 
converted into a voltage. This voltage can be amplified either linearly or logarithmically. Other 
conversions may be done to these values (e.g. compensation). This signal is then converted into a digital 
signal and reported on 1,024 channel (10-bit) scale. Signals are typically “binned” to fit into one of the 
channels. Logarithmic amplification can thus detect a larger range of fluorescent signal as the log 
amplified voltage is binned onto the 10-bit scale, allowing for greater discrimination between relative 
fluorescent intensities. Newer flow cytometers automatically convert the voltage into a digital signal and 
then amplify and process the signal. The immediate digitization of the voltage values increases the speed 
of the signal processing and removes the need for logarithmic amplification, avoiding the non-linearity of 
logarithmic amplification.  
 The signal detected from an individual cell will have a beginning (as it first passes into the laser) 
and an end (as it finishes passing through the laser), and an intensity over time. This can be integrated 
into a simple area measurement or simplified as a “height” (the highest amount of intensity recorded). 
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Some cytometers also have the ability to record the signal detected 10 million times a second, with those 
readings averaged to give the area or “height” measurements. 
 The signal detected from a cell will also vary with the abundance of fluorochrome there. The 
abundance of fluorochrome present, aka the fluorescence intensity or “brightness” will be a function of 
both the amount of thing being detected and the inherent “brightness” of the fluorochrome, as in the 
inherent intensity of light emitted from a fluorochrome. Some antigens are more highly expressed than 
others (e.g. CD45 vs. CD31 on leukocytes), which can vary for a given cell type, and certain 
fluorochromes are very bright (e.g. Phycoerytherin and Allophycocanin) and some are very dim (e.g. 
Pacific Blue).  
 These factors don’t play much of a role when analyzing single color fluorescence by flow 
cytometry. However, when multiple colors are used, this may become an important issue. This is because 
of two things: 1) In a sense, photomultipliers are “dumb” in that it detects whatever photons come near it. 
If you’re using more than one fluorochrome (fluorochrome A and B), 2) reality dictates that fluorochromes 
emit across a range of wavelengths as discussed previously. This wouldn’t be a problem except that if a 
cytometer has the appropriate filters linked to PMTs the emission from both fluorochrome A and B will be 
detected by the same PMT. This means that fluorescence will be detected and unable to be attributed to 
an individual color. Not to fear, math to the rescue! One can “compensate” for this by measuring the 
emission from each fluorochrome individually and detecting the ratio of the detected light in that PMT 
attributable to each color. Then the fluorochrome emission that is undesirably detected by a given PMT 
can be “subtracted” to give a truer level of the fluorescence emission. This is obviously more 
mathematically complex than conceptually described herein, involving linear algebra and other higher 
mathematical operations, but is essentially what the software on the computer is doing “behind the 
curtain” without the user being obvious to its doings. The drawback to using this mathematical 
normalization is that usually “spreading” is observed for cells that are compensated and have significant 
spillover/interaction from the fluorochrome[123,124]. Fluorescence measurements and detection on 
cytometers generally have a probabilistic nature to them. Due to this, the observed spillover will also have 
a stochastic nature to it. In a sense, some cells will show spillover and some won’t. Hence, when the 
mathematical “subtraction” is applied, the ones without spillover look negative, making the population as a 
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whole seem to be more variable than it really is. This is referred to as “spreading”. The best course of 
action is to use combinations of fluorophores that do not have “spillover” and other compensation issues. 
In certain cases this is unavoidable, but best practice dictates that this be minimized. 
 Most modern flow cytometry data can be easily manipulated with software used to perform all 
calculations. This allows for visual display of the data and quantification of the relative fluorescence. Data 
can be represented as single fluorescence histograms or fluorescence vs fluorescence plots for more in-
depth analysis.  
 Another feature of flow cytometry software is the “gating” that can be done with the software. This 
is a term used for selecting a group of cells and sub-analyzing only that population (e.g. fluorescence of 
other colors, FSC, SSC, etc.). Gating can be a useful tool for cleanly analyzing sub-populations of cells 
present in a mixture of cell types (e.g. different cell types within a tumor).  
 Flow cytometry is a powerful technique to analyze single cells. With any technique there are 
benefits and drawbacks. Correct application of flow cytometry can assist in analyzing therapeutics at a 
molecular level in complex cell mixtures (i.e. in vivo).  
1.5 Two photon microscopy 
 In fluorescence microscopy, one photon of light is absorbed by a fluorophore causing excitation of 
the electrons. This excited state is unstable, lasting only 10-8-10-9 seconds, and when the electrons return 
to their natural lower energy state, one photon of lower energy (longer wavelength) fluorescence is 
emitted[125]. Thus, fluorescence has traditionally been a linear process as if the power of excitation 
increases equally so does the emission.  
 In two photon microscopy, a non-linear absorption occurs whereby two photons of light are 
absorbed in a similar time frame (less than 10-18 seconds) to generate a fluorescent photon[125]. These 
photons are of roughly half the energy needed for traditional fluorescence excitation, however, due to 
quantum mechanics, the actual excitation wavelengths/spectra will vary slightly from this theoretical 
value. The emitting photons, however, behave as expected and show an emission spectra exactly as if 
excited by linear microscopy.  
 In her 1931 doctoral dissertation, Maria Göppert-Mayer predicted the possibility of two-photon 
absorption[126]. However, the simultaneous absorption of two low energy photons is a rare event, 
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requiring a high flux of photons of 1020-1030 photons/(cm2s ). This presented a technical challenge as 
most available arc lamps and other light sources were not able to generate the high flux required without 
simultaneously destroying the sample. It was not until the development of the subpicosecond (10-12s) 
pulse mode-locked laser and its demonstration of practical applicability in 1990[127]. This laser is able to 
generate ultrashort femtosecond (10-15s) pulses every nanosecond. Thus, a low average power can be 
used as the laser is not active 10,000 times more than it is active. In essence, the laser allows photons to 
be compressed in small units of time. A high numerical aperture allows for compression of the laser pulse 
into a small space, thus a coupling of the mode-locked laser and the appropriate aperture generates an 
extremely high photon flux in a small area, drastically increasing the probability of a two-photon excitation 
event.  
 The probability of an excitation event is related to the square of the instantaneous laser intensity 
(Probability α Intensity2). Due to this relationship, two photon excitation decreases dramatically away from 
the focal point. Thus, there is a lack of fluorescent photon emission that is out-of-focus, making two 
photon microscopy an inherently confocal-type of system not requiring a pinhole to filter out extraneous 
fluorescence as in linear confocal fluorescent microscopy. The pinhole needed in linear confocal 
microscopy also filters out a percentage of in-focus fluorescent photons. The deeper into a specimen 
imaging takes place, a greater percentage of photons filtered out would be in-focus fluorescent photons, 
creating an imaging depth limit to conventional linear microscopy of about 100µm. Thus, two photon 
microscopy has a superior imaging depth as compared to linear confocal microscopy ranging up to 1mm 
in ideal conditions, but roughly 6-fold better in most practical circumstances[128]. This is also aided by the 
fact that in biological samples, the longer wavelengths used by two photon imaging are less absorbed 
and affected by scattering as compared to conventional confocal microscopy. 
 From a theoretical perspective, the spatial resolution of two photon microscopy should be roughly 
half that as compared to linear confocal microscopy. Practically speaking, the only way to increase 
resolution can only be increased by increasing signal, requiring that linear confocal systems increase the 
pinhole size, resulting in more out-of-focus detection and thereby lowering resolution. Thus, in a practical 
setting the special resolution of two photon microscopy is nearly identical to linear confocal 
microscopy[125].  
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 One secondary benefit to two photon imaging is the second harmonic generation that occurs. 
This phenomenon is different than true two photon absorption as it is based on scattering rather than 
absorption of photons. When scattered, the photons combine to form photons roughly twice the energy of 
the incident photons. Generation of secondary harmonics requires that molecules lack inversion 
symmetry and are spatially ordered. Biologically, ordered structures like collagen fibers or microtubules 
create this phenomenon[129]. Thus, two photon imaging can incidentally also image collagen fibers while 
simultaneously causing fluorescence emission of a desired fluorophore.  
 Two photon microscopy has two main drawbacks at this time:  cost and accelerated 
photobleaching. Photobleaching in confocal microscopy has a somewhat linear relationship with the 
excitation power.  In two photon microscopy, photobleaching is accelerated as more photobleaching 
pathways are activated in addition to the observed higher order photobleaching. Though this only occurs 
in the focal plane, thinner samples (<10µm) are more prone to this issue[130,131]. 
 In sum, the use and application of two photon microscopy is gaining in widespread use. It has 
great potential and capabilities for in vivo imaging. The depth, resolution, inherent confocal nature, and 
automatic imaging of extracellular structures makes two photon microscopy extremely useful for 
understanding in vivo biology. 
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CHAPTER II: IN VITRO ANALYSIS OF PRINT NANOPARTICLE FACTORS INFLUENCING CELL 
ASSOCIATION WITH EWING SARCOMA SPHEROIDS REVEALS A CHARGE AND DOSE 
DEPENDENCY 
 
2.1 Overview 
 The signature of Ewing Sarcoma is the fusion protein EWS-FLI1. It has been shown that siRNA 
mediated knockdown can cause beneficial therapeutic effects in cell culture systems. However, delivery 
of siRNA in vivo presents unique challenges, requiring the use of a carrier. PRINT fabricated 
nanoparticles were examined for their suitability as an siRNA carrier in vitro. A spheroid culture model 
was used to mimic the 3-dimensional environment of a tumor. It was found that particle charge played a 
key role in determining the magnitude of cell association with particles, as determined by flow cytometry. 
Moreover, association was observed to plateau at higher doses of particles. However, confocal imaging 
suggests that the particles experience limited penetration into the spheroid. This implies that there may 
be a limit on particle association with cancer cells in vivo. 
 
2.2 Introduction 
 Ewing Sarcoma is characterized as a small round blue cell tumor, predominantly found in the 
axial skeleton regions. This cancer is identified by a signature genetic translocation resulting in a fusion 
protein between EWS and an ETS family protein[1-3]. Roughly 85% of all cases specifically contain an 
EWS-FLI-1 fusion, with the N-terminus of EWS and the C-terminal half of FLI-1. EWS is thought to be a 
protein involved in RNA processing, though it’s specific function is not well understood. FLI-1 is known to 
be a transcription factor, with an ETS domain in its C-terminus binding to the GGAA consensus 
sequence. Due to the presence of the ETS DNA binding domain in the fusion protein, the function of 
EWS-FLI is thought to be as a master regulator required for oncogenic transformation of the cells.  
 In a sense, Ewing Sarcoma is addicted to the EWS-FLI oncogene. Targeting this protein by 
siRNA-mediated knockdown results in growth inhibition of ewing sarcoma cell lines[4-9]. Based on this 
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result, EWS-FLI presents a very specific target with which to selectively inhibit ewing sarcoma cell growth 
as the translocation would only be found in the cancer cells.  Other groups have tried using various types 
of nanoparticles to deliver siRNA against EWS-FLI[10-15]. These have shown effectiveness at knocking 
down EWS-FLI in culture and some success at slowing or delaying tumor growth in vivo.  
 PRINT particles have the ability to carry an siRNA cargo. This can be done using a PLGA-based 
matrix coated or fabricated with cationic lipids such as DOTA or DOTAP[16]. Without these cationic lipids 
it is difficult to prevent the siRNA from leeching out of the particle. Alternatively, PEG hydrogel particles 
can be fabricated to carry siRNA cargoes[17]. The siRNA can be carried by the particle either by 
electrostatic interactions or by direct conjugation. Electrostatic binding is not suitable for in vivo conditions 
as physiologic salt conditions interfere with the electrostatic interaction and cause release of the siRNA. 
Direct conjugation is accomplished by attaching a sulfydryl group to the siRNA and creating a disulfide 
bonded siRNA covalently attached to the particle. This allows for release of the siRNA in the reducing 
conditions of the endosome, helping prevent premature release. Due to the presence of a plausible 
delivery system, it was decided to pursue PRINT siRNA delivery for Ewing Sarcoma. In vitro testing was 
undertaken to ascertain the optimal characteristics for PRINT particle delivery to Ewing Sarcoma cells. 
For these in vitro tests, a 3D culture system was used for evaluation. Essentially, a ball of cells was 
created to simulate the 3D nature of a tumor in vivo, termed a spheroid. This is in contrast to the 
conventional 2D culture system where cells are seeded on a flat surface. Spheroid models contain similar 
nutrient gradients found in tissue and have been shown to be more predictive of in vivo success than 
standard cultures[18-21]. In the experiments below, in vitro spheroid culture systems were used to probe 
for the optimal PRINT particle characteristics needed for successful siRNA delivery to Ewing Sarcoma 
cells.  
 
2.3 Experimental Methods 
2.3.1 Materials 
 Poly(ethylene glycol) diacrylate (MW 700) (PEG700DA), 2-aminoethyl methacrylate hydrochloride 
(AEM), diphenyl (2,4,6-trimethylbenzoyl)-phosphine oxide (TPO), and sucrose were purchased from 
Sigma-Aldrich. Thermo Scientific Dylight 488 maleimide, dimethylformamide (DMF), triethylamie (TEA), 
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pyridine, borate buffer (pH 8.6), acetic anhydride, and methanol were obtained from Fisher Scientific. 
Conventional filters (2 μm) were purchased from Agilent and polyvinyl alcohol (MW 2000) (PVOH) was 
purchased from Acros Organics. PRINT molds (80 nm x 80 nm x 320 nm) were obtained from Liquidia 
Technologies. Tetraethylene glycolmonoacrylate (HP4A) was synthesized in-house as previously 
described[22]. Methoxy-PEG(5k)-succinimidyl carboxy methyl ester (mPEG5k-SCM) was purchased from 
Creative PEGWorks. Typsin, DPBS, and cell culture media were purchased from Gibco. Fetal bovine 
serum was purchased from Cellgro. 
 
2.3.2 PRINT Nanoparticle Fabrication 
 The PRINT particle fabrication technique has been described previously in detail[23,24]. The 
preparticle solution was prepared by dissolving 3.5 wt% of the various reactive monomers in methanol. 
The reactive monomers included: a crosslinker made of an oligomeric PEG with a nominal molar mass of 
700 g/mol terminally functionalized on both end groups with an acryloxy functionality (PEG700DA); a 4 
repeat PEG chain containing a hydroxyl and an acrylate functional group (HP4A); an amine containing 
monomer (AEM) which served to provide the amine functionality used to conjugate PEG onto the surface 
of the PRINT particles; and in some cases a polymerizable fluorescent tag. In all cases a photoinitiator, 
TPO, was also added. The pre-particle solution was comprised of 68 wt% HP4A, 20 wt% AEM, 10 wt% 
PEG700DA, 1 wt% TPO and 1 wt% Dylight 488 maleimide or Dylight 650 maleimide. Using a # 3 Mayer 
rod (R.D. Specialties), a thin film of the pre-particles solution was drawn onto a roll of freshly corona 
treated PET, using a custom-made roll-to-roll lab line (Liquidia Technologies) running at 12 ft/min. The 
solvent was evaporated from this delivery sheet by exposing the film to a hot air dam derived from heat 
guns. The delivery sheet was laminated (80 PSI, 12 ft/min) to the patterned side of the mold, followed by 
delamination at the nip. Particles were cured by passing the filled mold through a UV-LED (Phoseon, 395 
nm, 3 SCFM N2, 12 ft/min). A PVOH harvesting sheet was hot laminated to the filled mold (140°C, 80 
PSI, 12 ft/min). Upon cooling to room temperature, particles were removed from the mold by splitting the 
PVOH harvesting sheet from the mold. 
 Particles were then harvested by dissolving the PVOH in a bead of water (1 mL of water per 3 ft 
of harvesting sheet). The particle suspension was passed through a 2µm filter (Agilent) to remove any 
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large particulates. To remove the excess PVOH, particles were centrifuged (Eppendorf Centrifuge 5417R) 
at ca. 21,000 g for 15 min, the supernatant was removed and the particles were re-suspended in sterile 
water. This purification process was repeated 4 times. 
 
2.3.3 Nanoparticle Characterization 
 Stock particle concentrations were determined by thermogravimetric analysis (TGA) using a TA 
Instruments Q5000 TGA. TGA analysis was conducted by pipetting 20µL of the stock nanoparticle 
solution into a tared aluminum sample pan. Samples suspended in water were heated at 30 °C/min to 
130 °C, followed by a 10 minute isotherm at 130°C. Samples suspended in DMF were heated at 30 
°C/min to 170 °C, followed by a 10 minute isotherm at 170 °C. All samples were then cooled at 30 °C/min 
to 30 °C, followed by a 2 minute isotherm at 30 °C. TGA was also performed on a 20µL aliquot of 
supernatant from a centrifuged sample of the stock nanoparticle solution to account for the mass of any 
stabilizer remaining in each sample. The concentration of stabilizer was subtracted from the concentration 
of stock particle solution to determine the actual particle concentration. Particles were visualized by 
scanning electron microscopy (SEM) using a Hitachi S-4700 SEM. Prior to imaging, SEM samples were 
coated with 1.5 nm of gold-palladium alloy using a Cressington 108 auto sputter coater. Particle size 
and zeta potential were measured by dynamic light scattering (DLS) on a Zetasizer Nano ZS (Malvern 
Instruments, Ltd.). 
 
2.3.4 PEGylation and Acetylation 
 After purification, the particles were reconstituted in DMF following the centrifugation 
technique outlined above and the concentration of particles in DMF was determined by TGA. The 
particles fabricated contain free primary amine groups which were used as functional handles to react 
with mPEG5k-SCM. The particles (1 mg NPs in 1 mL DMF) were reacted with TEA (100 µl) for 10 min at 
room temperature on a shaker plate (Eppendorf, 1400 rpm). The mPEG5k-SCM was dissolved in 
DMF(48mg/mL) and added to the reaction mixture (14 mg per mg NPs). The reaction mixture was shaken 
overnight and then quenched with borate buffer (100 μL). The nanoparticle solution was then washed 3 
times with DMF via centrifugation. Following PEGylation, particles were acetylated with acetic anhydride 
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to quench any unreacted amines and to yield a negative zeta potential. For acetylation, nanoparticles (1 
mg NP in 1 mL DMF) were reacted with an excess (10µl) of pyridine and acetic anhydride (7µl). The 
reaction was carried out in a sonicator bath (Branson Ultrasonic Cleaner 1.4 A, 160 W) for 15 min, after 
which a second addition of acetic anhydride (7µl) was added and the suspension was sonicated for 
another 15 min. Following acetylation, the particles were washed by centrifugation one time in DMF, 
followed by a borate buffer wash to neutralize any acetic acid side product, and then 3 washes with sterile 
water. Post-acetylation, particles were analyzed by TGA, DLS and SEM and stored at 4°C. 
 
2.3.5 Cells, cell culture, and particle dosing 
 Cells were cultured in cell specific medium for each Ewing Sarcoma cell line. Each media mixture 
included 1% Penicillin/Streptomycin (Gibco). EWS502 and EWS894 cells required 15% FBS (Gemini Bio-
products) in RPMI 1640 media (Gibco). A673 and MHH cells required 10% FBS in RPMI 1640. SKN-MC 
cells required Dulbecco’s minimum essential medium (Gibco) with 10% FBS, 1mM L-Glutamine (Gibco), 
and 1x Non-essential amino acids (Gibco). RD-ES cells use RPMI 1640 with 10% FBS and L-Glutamine 
and SK-ES were cultured with McCoy’s 5A (Gibco) with 15% FBS L-Glutamine. Hanging droplet 
spheroids were generated by trypsinization of the cells and resuspension to 20x105 cells/mL or a 
concentration such that twenty microliters would give a pre-determined amount of cells. Twenty 
microliters of the cell suspension was pippetted into a Nunc 60-well minitray (Thermofisher scientific cat# 
12-565-155). The minitray was inverted and placed in a 150mm dish containing three 35mm dishes filled 
with water (without lid) to provide local humidity and prevent evaporation of the liquid in the minitray. Cells 
were incubated at 37°C and 5% CO2 for 4-6 days to allow spheroid formation. Following spheroid 
formation, a maximum of 1-2ul of particles in water or water only was pipetted into each well used for 
experimentation. At least 10 wells per sample with 3 samples per group were used to quantify 
association. 
  
2.3.6 Flow cytometry of spheroids 
 Individual spheroids comprising one sample were collected into a single eppendorf tube and 
centrifuged. Spheroids were washed with PBS and then exposed to 100ul of 0.25% Trypsin (Gibco) at 
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room temperature for 3-5 minutes. FACS buffer (PBS with 2% FBS) was then added. The samples were 
analyzed with the Beckman-Coulter (Dako) Cyan ADP using the 488nm laser and the FITC emission filter 
(530/40). After forward and side scatter gating, particle association was determined by comparison of 
particle-dosed samples to the water only (0µg/mL) samples.  
 
2.3.7 Imaging of spheroid growth 
 Spheroids were imaged in the minitray under brightfield with a Zeiss Axiovert 200, a 10x 
objective, and camera. Images were taken of multiple spheroids 4 days after plating, with representative 
images shown here.  
 
2.3.8 Confocal imaging 
 After incubation with particles, multiple spheroids were fixed in 4% paraformaldehyde and 
contained on a slide. A triangluar chamber was constructed on a glass slide using broken coverslips and 
sealed with nail polish. The fixed spheroids were washed with 1xPBS and put in the chamber in solution. 
Excess solution was then carefully pipetted away and the chamber covered with a coverslip and sealed 
with nail polish. Spheroids were easily visible under the brightfield of a microscope and imaged. Images 
were obtained using an Olympus microscope. Both the 633 and 488nm lasers were used for excitation 
and emission was captured with an Alexa 647 and GFP filter, respectively. 
 
2.4 Results 
2.4.1 PRINT fabrication of Hydrogels 
 Nanoparticles were fabricated using the Particle Replication in Non-Wetting Templates (PRINT) 
technique.[1–3]. This method generates nanoparticles of highly consistent and precise size, shape, and 
composition. PRINT hydrogel nanoparticles composed of a covalently cross-linked hydrogel matrix. 
These were modified with various surface charges: either cationic, anionic, or PEGylated anionic. These 
particles were characterized by DLS and SEM and demonstrated a range of positive and negative zeta 
potentials and narrow size distributions (Figure 2.1). 
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2.4.2 Spheroid formation of Ewing Sarcoma cell lines 
 To explore the in vitro influence of particle characteristics on nanoparticle association, we wanted 
to use a spheroid cell culture model to represent the three dimensional nature of a tumor. It was unknown 
whether the Ewing Sarcoma cell lines available to me would form spheroids. The first experiment was to 
determine which cell lines would form a spheroid and what cell density was needed. The EWS502, 
EWS894, SK-N-MC, SK-ES, MHH, and RD-ES cell lines were tested at 500, 1000, and 2000 cells per 
well. The cells were incubated for 4 days and spheroid formation assessed. Images were obtained of the 
cultures and they definitively show that all Ewing Sarcoma cell lines tested formed spheroids (Figure 2.2). 
 
2.4.3 Effect of particle charge and dose 
 The next set of experiments examined the effects of particle charge and dose on the association 
of particles with cells using this spheroid model. This experiment examined the association of different 
surface charges of 80 x 80 x 320 nm hydrogel particles. A striking difference in association was observed 
for the differently charged particles (Figure 2.3). As a function of dose, association was dose-dependent 
until a plateau was reached. However, the dose at which the particles reached the plateau was strikingly 
different between differently charged particles. Cationic particles showed 70% association at 7.5µg/mL, 
whereas anionic particles show 70% association only at 30µg/mL. PEGylated anionic particles showed 
the least association as the maximum association of 40% was reached at 60µg/mL. These trends and 
relative amount of association was similar between two separate cell lines, EWS502 and A673. 
 
2.4.4 Confocal imaging of spheroid association 
 Spheroids were incubated with hydrogel nanoparticles and confocal imaging was performed to 
ascertain whether the particles were penetrating the spheroid. Images were taken of a Z-stack through 
the spheroid and collected into a montage. The spheroids expressed GFP, with the nanoparticle being 
fluorescently labeled with Dylight 650. From the images it is clear that the particles show minimal 
penetration to the middle of the spheroid (Figure 2.4).  
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2.5 Discussion 
 Spheroid formation is a suggestive measure of the ability of cells to form cancers in vivo due to 
the anchorage-independent growth it requires. However, this is not a property found in all cancer cell 
lines[25,26]. It is therefore surprising that all Ewing Sarcoma cell lines studied readily formed multicellular 
tumor spheroids. 
 It is well known that cationic particles efficiently associate with cells in vitro[27-32]. That PRINT 
particle charge dominates the resulting association or that cationic particles perform best is not surprising. 
However, the lack of penetrance of the spheroid is an intriguing observation. These data would suggest 
that in vivo the limiting factor for delivery of particles would be penetrating the tumor. This hypothesis has 
been investigated previously[33-35] and it does seem to play a role in particle diffusion into the tumor, 
however these studies tend to be more qualitative and image-based. Therefore, quantification of the 
fraction of cells receiving particles seem to lacking and could be an important piece of supporting data. 
Moreover, these studies focus on cancer cells. Tumors are a complex mixture of cell types[36-38]  and 
further examination of particle distribution on a cellular level may be informative, especially in vivo.  
 
2.6 Conclusions 
 In a spheroid culture system, modeling the 3-dimensional nature of solid tumors, particle 
association was shown to be dependent upon the surface charge. Association was also shown to plateau 
at a level depending on the surface charge. Confocal imaging suggests that the particles fail to penetrate 
the entirety of the spheroid, which is the most likely explanation for the association plateau. 
 
 
  Cationic  Acetylated  PEGylated  
Z-average  260.3  207.7  235.0  
PDI  0.107  0.045  0.104  
Zeta potential  15.9±6.49  -25.3±10.8 -16.4±7.29 
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Figure 2.1 SEM and DLS characterization of 80x320nm Hydrogel nanoparticles 
SEM image of Dylight 650 particles with DLS data in table at right. 
  
42 
 
 
Figure 2.2 Demonstration of spheroid formation ability of Ewing Sarcoma cells 
Various Ewing Sarcoma cell lines were counted, trypsinized and plated to form spheroids. Four days post 
plating the cells were imaged for spheroid formation. Each sample was created in duplicate with a 
representative image shown here.  
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Figure 2.3 Association of 80x320nm Hydrogel particles by dose, charge, and cell line in spheroids 
Various Ewing Sarcoma spheroids were incubated for 4 hours with 80x320nm Hydrogel PRINT particles 
of different surface charges. Flow cytometry was used to determine the percentage of cells associating 
with particles. Multiple spheroids (N=10) for each sample were used, with multiple samples (N=3) at each 
dose for each type of particle. The 0µg/mL dose was used to set a gate to determine the particle-positive 
cells. All error shown is ± SD (N=3 samples). 
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Figure 2.4 Confocal imaging of Ewing Sarcoma spheroids 
Confocal images of a spheroid dosed with fluorescently labeled hydrogel nanoparticles. The images are a 
Z-stack of a representative spheroid. 
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CHAPTER III: ANALYSIS OF PRINT NANOPARTICLE DISTRIBUTION WITHIN TUMORS         
REVEALS A CELL TYPE, SIZE, AND ROUTE OF ADMINISTRATION DEPEDENCY 
 
3.1 Overview 
 Delivery of impermeable cargo for cancer therapy will most likely require cell type specific 
delivery. Thus, we determined the intratumoral fate PRINT nanoparticles by multi-color flow cytometry 
and quantified the overall accumulation of particles to the organ by radiolabeling. Despite dose-
dependent accumulation of particles within the organ, particle association with cells became dose-
independent at high doses. At the cellular level, cancer cells had a small fraction of particle-positive cells 
whereas macrophages showed the greatest amount of association both by population and per cell. 
However, the majority of the particles associating with cells were associating with cancer cells due to their 
relative abundance in the tumor. Reducing particle size or administering particles intratumorally increased 
cancer cell association and decreased macrophage association. This study demonstrates the importance 
of cell-lineage specific analysis of nanoparticle fate in vivo. 
3.2 Introduction 
 The importance of the Enhanced Permeation and Retention effect for nanocarrier-mediated drug 
delivery in oncology has resulted in a focus on the accumulation of particles in whole tumors.[1] 
Nanoparticle targeting to solid tumors is typically quantified by one of a variety of whole organ methods 
that determine the fraction of the injected dose of the carrier or cargo that accumulates in an organ or 
tumor.[2–13] However, tumors are composed of numerous cell types in addition to cancer cells, including 
fibroblasts, endothelial cells, macrophages and neutrophils.[14–17] Whole organ approaches are unable 
to discriminate between accumulation in these cell types or in the extracellular space. For cargo with an 
intracellular mechanism of action, such as nucleic acids and proteins, the delivery to specific cell types is 
crucial to characterizing nanoparticle efficacy and optimizing targeting.  
50 
 
 Methods for the identification of intratumoral distribution include microscopy or flow cytometry. 
Confocal microscopy has been used to determine particle internalization in vivo by analyzing multiple 
sections of an organ.[18] However, meaningful quantification can be challenging. Flow cytometry permits 
concurrent cellular identification and nanoparticle quantification. Previous studies that have used flow 
cytometry to examine nanoparticle targeting to organs have not addressed the effects of particle 
characteristics (composition, shape, etc.) or dose on the accumulation in specific cells and do not 
correlate their findings with the whole organ.[19–21] Studies of nanoparticle targeting in tumors have 
focused exclusively on individual cell populations and, similarly to  organ-based studies, have not 
explored the effects of particle properties or dose.[14,22–25] Studies that take into account nanocarrier 
properties together with intra-organ or intra-tumor distribution will best inform nanoparticle optimization.  
 One advantage of using the PRINT fabrication method is that the particles are of monodisperse 
size. Using this top-down fabrication strategy using a mold confers the advantage of reproducible 
production of these monodisperse particles. If the particles had a large variation in size (i.e. PDI)  it is 
entirely possible that the size of the particle may cause preferential association with one cell population 
over another, confounding the results. This makes our results easier to interpret and analyze for the 
influence of particle characteristics on association with cells. PRINT also affords homogeneity in the 
composition of the particles and flexibility of choice in the desired nanoparticle material, bestowing a 
unique advantage among the other nanoparticle fabrication strategies. 
 Using a fluorescent mouse melanoma model and highly consistent PRINT nanoparticles, we 
found that a low fraction of cancer cells associate with particles. Moreover, on a per cell basis, 
macrophages associate with a greater amount of particles per cell. We also observe that particle size 
plays a significant role by increasing association with cancer cells.  
 
3.3 Experimental Methods 
3.3.1 Materials 
 Poly(ethylene glycol) diacrylate (Mw 700) (PEG700DA), 2-aminoethyl methacrylate hydrochloride 
(AEM), diphenyl (2,4,6-trimethylbenzoyl)-phosphine oxide (TPO), and sucrose were purchased from 
Sigma-Aldrich. Thermo Scientific Dylight 488 maleimide, dimethylformamide (DMF), triethylamie (TEA), 
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pyridine, borate buffer (pH 8.6), acetic anhydride, and methanol were obtained from Fisher Scientific. 
Conventional filters (2 μm) were purchased from Agilent and polyvinyl alcohol (Mw 2000) (PVOH) was 
purchased from Acros Organics. PRINT molds (80 nm x 80 nm x 320 nm) were obtained from Liquidia 
Technologies. Tetraethylene glycolmonoacrylate (HP4A) was synthesized in-house as previously 
described[26]. Methoxy-PEG(5k)-succinimidyl carboxy methyl ester (mPEG5k-SCM) was purchased from 
Creative PEGWorks. Typsin, DPBS, and cell culture media were purchased from Gibco. Fetal bovine 
serum was purchased from Cellgro. 
 
3.3.2 PRINT Nanoparticle Fabrication 
 The PRINT particle fabrication technique has been described previously in detail[27,28]. The 
preparticle solution was prepared by dissolving 3.5 wt% of the various reactive monomers in methanol. 
The reactive monomers included: an oligomeric PEG with a nominal molar mass of 700 g/mol terminally 
functionalized on both end groups with an acryloxy functionality (PEG700DA); a 4 repeat PEG chain with 
a hydroxyl and acrylate functionalities (HP4A); an amine containing monomer (AEM) which served to 
provide the amine functionality used to conjugate PEG onto the surface of the PRINT particles; and in 
some cases a polymerizable fluorescent tag. In all cases a photoinitiator, TPO, was also added. The pre-
particle solution was comprised of 67.75 wt% HP4A, 20 wt% AEM, 10 wt% PEG700DA, 1 wt% TPO and 
1.25 wt% Dylight 488 maleimide. Using a # 3 Mayer rod (R.D. Specialties), a thin film of the pre-particles 
solution was drawn onto a roll of freshly corona treated PET, using a custom-made roll-to-roll lab line 
(Liquidia Technologies) running at 12 ft/min. The solvent was evaporated from this delivery sheet by 
exposing the film to a hot air dam derived from heat guns. The delivery sheet was laminated (80 PSI, 12 
ft/min) to the patterned side of the mold, followed by delamination at the nip. Particles were cured by 
passing the filled mold through a UV-LED (Phoseon, 395 nm, 3 SCFM N2, 12 ft/min). A PVOH harvesting 
sheet was hot laminated to the filled mold (140°C, 80 PSI, 12 ft/min). Upon cooling to room temperature, 
particles were removed from the mold by splitting the PVOH harvesting sheet from the mold. 
Particles were then harvested by dissolving the PVOH in a bead of water (1 mL of water per 3 ft of 
harvesting sheet). The particle suspension was passed through a 2µm filter (Agilent) to remove any large 
particulates. To remove the excess PVOH, particles were centrifuged (Eppendorf Centrifuge 5417R) at 
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ca. 21,000 g for 15 min, the supernatant was removed and the particles were re-suspended in sterile 
water. This purification process was repeated 4 times. 
 
3.3.3 Nanoparticle Characterization 
 Stock particle concentrations were determined by thermogravimetric analysis (TGA) using a TA 
Instruments Q5000 TGA. TGA analysis was conducted by pipetting 20µL of the stock nanoparticle 
solution into a tared aluminum sample pan. Samples suspended in water were heated at 30 °C/min to 
130 °C, followed by a 10 minute isotherm at 130°C. Samples suspended in DMF were heated at 30 
°C/min to 170 °C, followed by a 10 minute isotherm at 170 °C. All samples were then cooled at 30 °C/min 
to 30 °C, followed by a 2 minute isotherm at 30 °C. TGA was also performed on a 20µL aliquot of 
supernatant from a centrifuged sample of the stock nanoparticle solution to account for the mass of any 
stabilizer remaining in each sample. The concentration of stabilizer was subtracted from the concentration 
of stock particle solution to determine the actual particle concentration. Particles were visualized by 
scanning electron microscopy (SEM) using a Hitachi S-4700 SEM. Prior to imaging, SEM samples were 
coated with 1.5 nm of gold-palladium alloy using a Cressington 108 auto sputter coater. Particle size 
and zeta potential were measured by dynamic light scattering (DLS) on a Zetasizer Nano ZS (Malvern 
Instruments, Ltd.). 
 
3.3.4 PEGylation and Acetylation for in vitro and in vivo studies 
 After purification, the particles were reconstituted in DMF following the centrifugation 
technique outlined above and the concentration of particles in DMF was determined by TGA. The 
particles fabricated contain free primary amine groups which were used as functional handles to react 
with mPEG5k-SCM. The particles (1 mg NPs in 1 mL DMF) were reacted with TEA (100 µl) for 10 min at 
room temperature on a shaker plate (Eppendorf, 1400 rpm). The mPEG5k-SCM was dissolved in 
DMF(48mg/mL) and added to the reaction mixture (14 mg per mg NPs). The reaction mixture was shaken 
overnight and then quenched with borate buffer (100 μL). The nanoparticle solution was then washed 3 
times with DMF via centrifugation. Following PEGylation, particles were acetylated with acetic anhydride 
to quench any unreacted amines and to yield a negative zeta potential. For acetylation, nanoparticles (1 
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mg NP in 1 mL DMF) were reacted with an excess (10µl) of pyridine and acetic anhydride (7µl). The 
reaction was carried out in a sonicator bath (Branson Ultrasonic Cleaner 1.4 A, 160 W) for 15 min, after 
which a second addition of acetic anhydride (7µl) was added and the suspension was sonicated for 
another 15 min. Following acetylation, the particles were washed by centrifugation one time in DMF, 
followed by a borate buffer wash to neutralize any acetic acid side product, and then 3 washes with sterile 
water. Post-acetylation, particles were analyzed by TGA, DLS and SEM and stored at 4°C. 
 
3.3.5 Cells, cell culture, and spheroid injections 
 LKB498 cells were cultured are previously described[29] in high glucose DMEM (Gibco) with 10% 
FBS (Gemini Bio-products) and 1% Penicillin/Streptomycin (Gibco). Hanging droplet spheroids were 
generated by trypsinization of the cells and resuspension to 20x105 cells/mL. Twenty microliters of the cell 
suspension was pippetted into a Nunc 60-well minitray (Thermofisher scientific). The minitray was 
inverted and placed in a 150mm dish containing three 35mm dishes filled with water(without lid) to provide 
local humidity and prevent evaporation of the liquid in the minitray. Cells were incubated at 37°C and 5% 
CO2 for 4-6 days to allow spheroid formation. Individual spheroids were harvested and placed into 80 μL 
media in a 0.5 mL microcentrifuge tube. Single spheroids in the tube were verified visually under a 
brightfield microscope and were placed on ice until time of injection. Athymic nude mice were 
anesthetized by inhalation with 2% isoflurane. A 14-mL conical tube was taped onto a heating pad next to 
the isoflurane nose cone under an Olympus MVX10 Macroview macroscope. The MVX10 is equipped 
with a MVPLAPO 1x objective, total mag 6.3–63x, NA 0.25, W.D. 65 mm. The mouse ear was affixed 
onto the conical tube with double-sided tape. The tumor spheroid, which was visible to the unaided eye in 
the tube, was drawn into a 10-μL glass syringe (Hamilton) with a custom 1-inch 27G needle in a total 
volume of 2–3 μL media. The glass syringe was held vertically for 1 min to allow the tumor spheroid to 
settle into the needle. While observing the ear through the macroscope, the needle (bevel facing up) was 
pierced into the dermis of the mouse ear and the spheroid in media was injected, which resulted in a 
transient visible bump under the surface of the skin. Successful spheroid injection was verified 
immediately by epifluorescence imaging with the MVX10 Texas Red filter. 
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3.3.6 Mice and Particle Injections 
 All animals were handled according to the NIH Guide for the Care and Use of Laboratory 
Animals. All procedures were approved by the University of North Carolina-Chapel Hill Institutional Animal 
Care and Use Committee (IACUC), protocol #11-154.0. All tumor spheroid injections were performed 
under inhalable isofluorane anesthesia and all efforts made to minimize animal discomfort as described 
previously[29]. All intravenous injections were done in concert with the UNC Animal Services Core. 
Suspensions of nanoparticles were made in isotonic 9.25% Sucrose and a maximum of 300µl per animal 
was injected via the tail vein for systemic administration. All animals herein are 4-8 week old, male 
Foxn1nu (athymic; C57BL/6J background) nude mice purchased from the UNC Animal Services Core. 
Tumors were of equal volumes between groups and ranged from 100-300mm3, as determined using 
caliper measurements and the equation V = (L/2)x(W/2)x(H/2)x(4/3xπ). For the dose experiment, particles 
were resuspended at different concentrations (1.45, 4.65, 14.65mg/mL) to give similar injection volumes 
around 300µl. 
 
3.3.7 Tumor Dissociation and Flow Cytometry 
 Tumors were harvested following animal sacrifice and placed in a 15mL conical tube containing a 
solution of 4.5mL DMEM with 10% FBS on ice.  The conical tube was placed in a sterile tissue culture 
hood where 0.5 mL of a 3000U/mL Collagenase, 1000U/mL Hyaluronidase, 1000mg/L D-Glucose DMEM 
solution (“10x Collagenase/Hyaluronidase”, StemCell Technologies, cat#07912) was added, with the 
conical tube then being placed in a 37°C incubator.  Every 30 minutes for 1.5 hours the tubes were 
inverted to mix the solutions. After 1.5 hours, a plastic pipette was used to gently break up clumps of 
tissue.  The conical tube was then placed back in the incubator for 1.5 hours, with inversion mixing every 
30 minutes.  Samples were then centrifuged at 600g for 5 minutes. Supernatant was discarded and 
samples were resuspended with a 1:4 mixture of HBSS+2%FBS (HF):0.8% NH4Cl and 0.1mM EDTA in 
water (“RBC lysis buffer”, Stem Cell Technology, cat#07850). Samples were centrifuged at 450g for 5 
minutes and resuspended in RBC lysis buffer. After a 5 minute centrifugation at 450g, samples were 
resuspended in 5mL of 0.05% Trypsin 0.53mM EDTA solution (Gibco) and incubated for 5 minutes at 
37°C.  The Trypsinization was stopped with 10mL of HF.  Following centrifugation at 600g for 5 minutes, 
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samples were resuspended in 4.5 mL of 1U/mL Dispase in DMEF-12 (Stem Cell Technologies, 
cat#07923) and 0.5mL of a 1mg/mL Bovine Pancreas DNAse I-PBS solution (Stem Cell Technologies, 
cat#07900).  This mixture was incubated for 30 minutes at 37°C when 10 mL of HF was added to the 
sample.  The sample was then filtered using a 40µm cell strainer (Fisher scientific, cat#22-363-547) and 
centrifuged at 450g for 5 minutes.  Cells were resuspended in HF, placed on ice, and counted with a 
hemocytometer.  Cells were then washed with PBS and resuspended to a concentration of 2x106 cells/mL 
in PBS, with 1mL of cells being transferred to a 1.5mL eppendorf tube.  Live-Dead Fixable Blue 
(Invitrogen, cat#L-23105) was then added at a concentration of 1ul/4x106 cells in 1mL PBS and incubated 
on ice for 15 minutes, protected from light. Cells were washed with PBS and resuspended in 100µl PBS. 
Fc Block (BD Biosciences cat#553142) was incubated at a concentration of 2ul/106 cells  for 5 minutes on 
ice, protected from light. PE-Cy7 CD31 (Clone 390, cat#102418), APC F4/80 (Clone BM8, cat#123116), 
Alexa 700 Ly6G (Clone 1A8, cat#127622), and Pacific Blue CD45 (Clone 30-F11, cat#103126) antibodies 
(Biolegend) were added to the cells and incubated for 1 hour on ice. Cells were then washed with PBS 
and resuspended in 500µl of 4% paraformaldehyde. After a 15 minute incubation at room temperature, 
cells were washed twice with FACS buffer (2%FBS in PBS), then resuspended in a final volume of 500µl 
of FACS Buffer and stored at 4°C until data acquisition on the BD LSRII using FACSDiva. Data analysis 
of FCS3 files was performed using FlowJo version 10.6. All surface markers were compared to their 
fluorescence minus one (FMO) controls to set appropriate gates. Particle association was determined by 
comparison to sucrose injected animals to determine appropriate gating.  
3.3.8 Calculating the relative intratumoral distribution of particles by fluorescence 
 The percentage of particle-positive cells was multiplied by their relative proportion in the sample. 
(e.g. 6% particle-positive cancer cells x 90% of the sample). This value was then multiplied by the mean 
fluorescence intensity of those particle positive cells to give a relative fluorescence value. Addition of all 
resulting fluorescence values gave a sum of total fluorescence. Dividing the value for each sub-population 
by the total gave a percentage of particles within that cellular compartment. 
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3.3.9 Radiation 
 High specific activity 64Cu (14000±7600 Ci/mmol or 518±28 TBq/mmol) was obtained from the 
Washington University School of Medicine (St. Louis, MO, USA). 64Cu was produced on a CS-15 
biomedical cyclotron by the 64Ni(p,n)64Cu nuclear reaction using previously established methods[30], with 
a half-life of 12.7 hours. Particles were PEGylated as described above. Following PEGylation, particles 
were characterized as described above by TGA and reacted in 0.1 M Na2CO3 buffer (pH 9) with 2-(4-
isothiocyanatobenzyl) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (p-SCN-Bn-DOTA) at 5 
mg/mL (2:1 DOTA:AEM molar ratio). A conversion from positive to negative zeta potential indicated that 
the reaction went to completion. Particles were then incubated with 64CuCl2 for 30 minutes at 65 °C in 0.1 
M ammonium acetate, washed 3 times by centrifugation with deionized water, and resuspended for 
injection in 9.25% sucrose. 
 
3.3.10 Two-photon Microscopy 
 Tumor-bearing animals with tumors between 10-30mm3 were imaged as previously described. 
Animals were anesthetized with isofluorane, and tumors were imaged before and after administration of 
particles. All imaging was performed at 910nm with an Olympus FV1000MPE mounted on an upright BX-
61WI microscope, using a 25x, 1.05 N.A. (2 mm W.D.) water immersion objective to capture images. 
Software and microscope settings were consistent for all acquired images (the laser power was at 14% 
and each channel’s PMT voltage was 580, 635, and 600, respectively). The laser unit is a MaiTai 
DeepSee tunable from 690–1040 nm with a pulse width < 100 fs. There were 3 Channel Non-descan 
Detectors used, Ch1 (420–460 nm) BFP, Ch2 (495–540nm) GFP, Ch3 (575–630 nm) RFP.  
 
3.3.11 Statistics 
 All plotted data, unless otherwise noted, were analyzed using a one-way ANOVA and Tukey’s 
post-hoc analysis. Mean Fluoresence data was analyzed using a two-way ANOVA and Tukey’s post-hoc 
analysis. 
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3.4 Results 
3.4.1 PRINT fabrication 
 To explore the influence of particle characteristics on nanoparticle association, we used an 
established mouse melanoma model in which LKB498 cancer cells stably express the red fluorescent 
protein Td Tomato.[29] Tumor cells were inoculated intradermally and allowed to grow to a size of 
100mm3. Nanoparticles were fabricated using the Particle Replication in Non-Wetting Templates (PRINT) 
technique.[27,28,31]. This method generates nanoparticles of highly consistent and precise size, shape, 
and composition. The PRINT nanoparticles were composed of a covalently cross-linked hydrogel matrix. 
Particles of 80 nm x 80 nm x 320 nm were fabricated and PEGylated as previously described.[27] 
Depending on the assay, fluorescent moieties were incorporated or copper-64 (64Cu) was chelated to the 
particles. Particles were characterized by DLS and SEM and demonstrated a similar negative zeta 
potential and narrow size distribution (Figure 3.1). 
 
3.4.2 Accumulation of particles in whole organ 
 To determine nanoparticle accumulation using a whole-organ based approach, we injected 64Cu 
radiolabeled PRINT nanoparticles at several doses into tumor bearing mice. Eighteen hours following 
particle administration animals were sacrificed, organs were harvested and gamma emission was 
measured. There was a wide distribution in the fractional association across organs ranging from ~45% of 
particles associating with the liver to ~0.2% of particles associating with the heart. These data are 
consistent with other types of nanoparticles. The fraction of the injected dose detected in each organ was 
consistent across the 3 doses (Figure 3.2a) indicating that the relative accumulation is independent of the 
dose administered. The total amount of particles contained within the tumor as well as in each organ 
increases in a dose-dependent manner (Figure 3.2b, c).  
 
3.4.3 Sub-organ Particle Accumulation by Flow Cytometry and the Effect of Dose 
 We then examined the cellular composition of our tumor model. Tumors were enzymatically 
dissociated to create a single cell suspension and analyzed using multi-color flow cytometry (Figure 3.3). 
After gating on live cells, cancer cells (as distinguished from tumor cells which represents the mixture of 
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all cells in the tumor) were identified by Td Tomato fluorescence. The remaining non-cancer cells were 
separated into immune cells by CD45 expression (leukocyte marker). CD45+ cells were further analyzed 
for the expression of F4/80 which marks mouse macrophages or Ly6G which marks neutrophils. 
CD45+F4/80-Ly6G- cells were classified as “other leukocytes” representing a mixture of cells that includes 
natural killer cells, dendritic cells, and B cells. CD31 surface expression in the CD45- cell population 
identified endothelial cells, with the remaining CD45- CD31- classified as fibroblast/other. Surface markers 
were compared to their fluorescence minus one (FMO) controls to ensure appropriate population gating. 
The tumor cell suspension reproducibly contained 89.9% cancer cells, 3.2% neutrophils, 1.1% 
macrophages, 0.64% other leukocytes, 0.49% endothelial cells, and 3.3% fibroblast/other cells (Figure 
3.4). This strategy accounts for virtually every cell (98.6%) present in the tumor. 
 Mice were injected with fluorescent 80 x 80 x 320 nanoparticles at several doses (or with a 
sucrose control) as before. 18 hours after treatment tumors were dissected from mice, dissociated and 
analyzed by flow cytometry as described. Cancer cells demonstrated a dose-dependent association at 
doses between 12.5 to 40 mg/kg yielding 1.5% or 5.2% particle positive cells, respectively (Figure 3.5a). 
At the 125 mg/kg dose level, however, 6.2% association was observed. These data indicate a dose 
dependent increase in fractional association that seems to plateau at higher doses. Non-cancer cell 
populations showed a greater percentage of particle association. Roughly 60-80% of macrophages 
(Figure 3.5b) and 20-60% of neutrophils and other leukocytes (Figure 3.5c,d) were associated with 
PRINT particles. Approximately 15-35% of endothelial cells were positive for particle association (Figure 
3.5e) with fibroblast/other cells having the lowest fractional association of 5-20% (Figure 3.5f). Strikingly, 
whereas macrophages and cells in the other leukocyte class demonstrate a sustained dose-dependent 
increase in nanoparticle association, cancer cells as well as endothelial cells and cells in the 
fibroblast/other class show no increase in fractional association above the 40 mg/kg dose. 
 In contrast to the fractional uptake described above which represents association across the 
population of cells, we also quantified fluorescence for individual cells. Among the cells analyzed, 
macrophages demonstrated the greatest mean fluorescence intensity (MFI) (Figure 3.6). MFI for 
macrophages was approximately 3.5 fold greater than that of the cancer cells, indicating that 
macrophages associate with a greater number of particles per cell. Like fractional association, 
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fluorescence signal per cell increased in a dose-dependent fashion at the low doses for cancer cells as 
well as immune cells. However, signal in cancer cells plateaued despite a three-fold increased dose. 
These data suggest that there is a limited fraction of cells that are able to associate with particles and that 
these cells have a biological limitation on the amount of nanoparticles they are able to take up. Using 
fluorescence, we also sought to quantify how much of the dose of particles were going to each cell type. 
Multiplying the mean fluorescence intensity by the percentage of particle-positive live cells for each cell 
type, we reasoned that this number represented the fraction of particle dose within the tumor associating 
with a given cell type. Adding this number to similar quantifications for other cell types, it was expressed 
as a percentage of particles associating with cells (Figure 3.7). This quantification suggests that particle-
positive cancer cells represent 50% of the dose of particles associating with cells. Particle-positive 
macrophages represent 20-40% of the dose, with neutrophils representing 15-30%. Other leukocytes, 
endothelial cells, and fibroblast/other cells all account for 1-2% each. 
 
3.4.4 Effect of Particle Size on Association 
 We then examined the influence of particle size on intratumoral cellular association. 55 x 70 nm 
particles were fabricated and functionalized as before (Figure 3.8). 55 x 70 nm and 80 x 320 nm particles 
were dosed at 25 mg/kg. Compared with the 80 x 320 nm particles, the 55 x 70 nm particles resulted in 
nearly twice the association with cancer cells (4.5 % vs 2.5%) as well as increased macrophage 
association (65% vs 37%) (Figure 3.9a,b).  In contrast, neutrophils, other leukocytes, endothelial cells, 
and fibroblast/other cells exhibited similar fractional association (Figure 3.9c-f). These data suggest that 
the 55 x 70 nm particles associate with more cancer cells than 80 x 320 nm particles of similar chemical 
composition. The mean fluorescence intensity of the particle-positive cells was roughly similar across 
particle sizes (Figure 3.10) indicating that the cells associate with a similar particle mass. Quantification of 
the percentage of associating particle dose suggests that the dose associating with cancer cells doubles 
when 55 x 70 nm particles are used as compared to 80 x 320 nm particles (Figure 3.11). All other cell 
populations remain relatively constant in the fraction of associating particle dose.  
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3.4.5 Effect of Route of Administration on Association 
 Intravenous administration of particles must overcome several hurdles in order to reach the cells 
of interest. Intratumoral administration therefore may be a useful mode of administration and was 
examined for its performance. Using 80 x 320 nm particles as above, a 25mg/kg dose was administered 
intravenously or intratumorally. The fraction of cancer cells associating with particles increased two-fold 
as compared to intravenous administration (Figure 3.12a). Endothelial cells and fibroblast association 
was unchanged (Figure 3.12b, c). In contrast, neutrophil, macrophage, and other leukocyte cell 
association was slightly decreased (Figure 3.12d, e, f). Mean fluorescence intensity demonstrated a 3-
fold increase in the amount of fluorescence per cancer cell, with most other cell types showing no 
difference (Figure 3.13). The fraction of dose associating with cancer cells more than doubles when 
particles are administered IT (Figure 3.14). Macrophages, neutrophils, and other leukocytes are all 
observed to have less fractional dose associating with those cell types. Endothelial cells and 
fibroblast/other are relatively similar.  
3.4.6 In vivo two photon microscopy 
 Flow cytometry is a powerful tool, but is unable to give a definitive picture of how the particles are 
interacting with the 3-dimensional architecture of the tumor. For that, in vivo two-photon microscopy was 
used to visualize fluorescent particle distribution within LKB498 tumors. To collect baseline information, 
the contralateral ear of a tumor-bearing mouse was used. Using 80 x 320 nm particles as before and a 
40mg/kg dose, particles were injected intravenously. Images were taken of the normal ear both before 
and 18 hours after injection of particles. This data suggests that in normal dermis, particle diffusion is 
quite limited to the area in or immediately around blood vessels (Figure 3.15). Particles can be seen 
contained in veins and aggregating in capillaries. From this baseline information, tumored ears were 
serially imaged following particle injection. Images were collected pre- and post-injection. This data 
reveals that particles are visible within the tumor as early as 10 minutes after injection (Figure 3.16a). 
Particle signal shows weak colocalization with cancer cells and strong colocalization with host cells, 
presumably immune or macrophage cells. (Figure 3.16a, b) Over time, nanoparticle fluorescence fades 
from the cancer cells and seems to stay constant in the host cells. (Figure 3.16a) 
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3.5 Discussion 
 To understand intratumoral distribution of nanoparticles we compared single-cell analysis to 
whole-organ accumulation using highly uniform PRINT nanoparticles. We observed a striking discordance 
between whole-tumor and individual cell analysis. Whole-organ quantification demonstrated dose-
dependent accumulation. In contrast, single-cell based analysis revealed that delivery to cells becomes 
dose-independent at higher doses for cancer cells. Flow cytometry also enabled us to examine individual 
populations of cells within the tumor. We observed that macrophages associate with more particles per 
cell as compared to cancer cells. In vivo imaging reinforces the idea that host immune cells colocalize 
with significant amounts of particles. Moreover, that diffusion of the particles from blood vessels is quite 
pronounced in the tumor as compared to normal dermis. Particle properties also influenced intratumoral 
particle distribution as reduced particle size increased cancer cell association. 
 Single-cell assessment permits lineage-specific quantification of nanoparticle association. 
Biologically active membrane-impermeable cargo requires cell-specific delivery. The discrepancy 
between whole organ and single cell assessment limits the way accumulation experiments can be 
interpreted. A possible reason for this is that at higher doses, particle accumulation is predominantly in 
the extracellular space. A plausible explanation for this is that cells near blood vessels have a limit to their 
capacity to associate with particles. Thus, particles at higher doses continue to be deposited into the 
extracellular space. Secondarily, despite the low abundance of macrophages within the tumor, the 
fraction of dose going to the macrophages may be disproportionate due the high per cell association of 
macrophages. This fact was visually supported by the in vivo two-photon imaging as Td Tomato 
expressing cells had low colocalization of particles, whereas host cells, presumably macrophages had the 
brightest fluorescence. This could be due to macrophages being near the available blood vessels or 
diffusion into the tumor itself. The declining or disappearing of particle signal in the cancer cells could be 
attributable to multiple processes:  particle degradation, cancer cell mitosis, or cancer cell death. The 
particles have covalent carbon-carbon bonds making degradation of the particle a slow process and an 
unlikely culprit. Cancer cell death is also unlikely due to the numerous in vitro studies showing negligible 
cytotoxicity of this particle type across many cancer types. Thus, it is most likely cancer cell mitosis that 
causes a dilution effect of the particle fluorescence.  
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 Use of PRINT nanoparticles allows us to carefully examine the influence of particle properties on 
cell association. One factor we examined was particle size. Reduction in particle size had a seemingly 
specific effect on increasing cancer cell association. Since an equivalent dose (by mass) of a smaller 
particle will yield greater numbers of particles, it is possible that the increased number of particles will 
augment delivery of the particles beyond the capillary bed of the tumor. Smaller sized particles may also 
penetrate the tumor more efficiently, coming in contact with more cancer cells. Nonetheless, this study 
supports our hypothesis that particle-specific features will influence intratumoral distribution and these 
features could be manipulated to target cell populations in tumors and organs. Mean fluorescence 
intensity was similar for both sized particles indicating that a similar mass of particles is contained in each 
cell. For a given mass, there are roughly 9.6 times as many 55 x 70 nm particles as compared to 80 x 320 
nm particles. Hence, for the mean fluorescence data it seems to indicate that each cell contains a similar 
mass of particles, though roughly 9.6 times greater number of 55 x 70 nm particles in each cell than 80 x 
320 nm particles. The role that particle number plays in cell association is unclear from these studies. 
Moreover, the role that particle number plays in efficacious delivery of therapeutics is quite opaque. 
Greater numbers of particles may provide greater diffusive force into the tumor. It is possible that large 
numbers of particles may decrease the clearance of particles from the blood, allowing greater contact 
with cancer cells. Clearly, from the 80 x 320 data there is a limit to the influence that particle number has 
on cell association. What contribution particle number has on increased association in addition to particle 
size is difficult to discern from the experiments here. That the greater number of 55 x 70 nm particles 
present at a given mass is solely responsible for the increase in association seems unlikely, but may play 
a role for the difference in association observed here. 
 Route of administration also seemed to play a role in the relative association of the various cell 
types. Intratumoral administration was observed to shift particle distribution to cancer cells and away from 
phagocytic cell types like macrophages, neutrophils, and other leukocytes. Most of the animals in the 
intratumoral group were unable to contain the full volume of particles administered. That the data shows a 
significant shift despite this experimental issue is compelling and suggests that the actual benefit may be 
greater than observed here.  
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3.6 Conclusions 
 In conclusion, we have developed an approach to quantify specific nanoparticle uptake across 
the cellular compartments that constitute a tumor. Moreover, we demonstrated that particle characteristics 
can influence the association with these compartments. While flow cytometry is a powerful technique, in 
this application it is unable to discriminate whether the particles are surface bound or internalized in cells. 
The analysis of nanoparticle accumulation on a cellular level using two photon in vivo imaging supports 
the conclusions made by flow cytometry. Importantly, these experiments demonstrate that organ-level 
analysis of accumulation does not completely correlate with particle association with cells. We suspect 
that the difference results from deposition or retention of nanoparticles in the extracellular space. Cellular-
level quantification is particularly relevant when delivering cargo that depends on an intracellular 
mechanism. 
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Figure 3.1 SEM and DLS of 80x320nm Hydrogel particles conjugated with DOTA 
SEM image of 80x320nm particles, with resulting DLS values in the top left corner.  
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Figure 3.2 Accumulation of particles in tumors as measured by 64Cu radioactivity 
A) Calculated percent injected dose for each organ. B) Calculated amount of nanoparticles contained 
within the tumor for each dose administered. C) Calculated amount of nanoparticles contained within all 
organs for each dose administered. All error shown is ± SD (N=4). 
  
C 
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Figure 3.3 Flow cytometry gating scheme for analysis  
Pictorial representation of flow cytometry gating scheme for cell population identification. Representative 
histograms are shown for helpful reference. In single color histograms, the grey line is the FMO control, 
with the black line representing a sample. 
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Figure 3.4 Resulting proportion of cell populations detected from gating scheme 
After gating, the percentage of each cell population was expressed as percentage of all gated live cells. 
This data represents two experiments, encompassing particle and non-particle dosed animals, with the 
combined data shown here. The error is ±SD (N = 32). 
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Figure 3.5 Particle association as a function of dose 
Particle association for each sub-population was determined across the 4 dose groups and quantified 
using the sucrose administered animals as the particle FMO. Association is expressed as the percentage 
of particle positive cells for each sub-population. A representative histogram is shown to the left of the 
quantitation. Error shown is ±SD (N=4 per dose group). The * symbol represents p<0.05 vs 0mg/kg and # 
represents p<0.05 vs 12.5mg/kg dose. 
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Figure 3.6 Mean fluorescence intensity when different particle doses are administered 
Quantification of the relative fluorescence in each particle-positive population as gated and quantified in 
Figure 3.5. 
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Figure 3.7 Distribution of cell-associated particles as a function of particle dose 
Using the same dataset generated in Figure 3.5, the percentage of total fluorescence in each population 
relative to the whole sample is shown here. This gives a relative measure of the percent of cell-
associated particles contained within each population. The error is ±SD (N = 4 per dose). 
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Figure 3.8 SEM of 55x70nm particles 
SEM images were taken of the 55x70nm particles used in subsequent experiments. 
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Figure 3.9 Quantification of the particle association for differently sized particles 
Animals were administered either 80x320nm or 55x70nm particles. Gating and quantification of 
association was performed as shown in previous figures. Error shown is ±SD (N=6 per group). The * 
symbol represents p<0.05 vs Sucrose and # represents p<0.05 vs 80 x 320 nm particles. 
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Figure 3.10 Mean fluorescence intensity when administering differently sized particles 
Quantification of the mean fluorescence of the particle positive cells as determined in figure 3.9. Error 
shown is ±SD (N=6 per group). 
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Figure 3.11 Distribution of cell-associated particles as a function of particle size 
Using the same dataset generated in Figure 3.9, the percentage of cell-associated particles contained 
within each sub-population, as measured by fluorescence, as a function of particle size. Error shown is 
±SD (N=6). 
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Figure 3.12 Particle association as a function of route of administration 
Intravenous injection (blue bars) and intratumoral injection (red bars) was compared. The percent of 
particle association was calculated as previously stated.  Error shown is ±SD (N=6). The * symbol 
represents p<0.05 vs Sucrose and # represents p<0.05 vs the IV dose. 
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Figure 3.13 Mean fluorescence in each sub-population as a function of route of administration 
The mean fluorescence of the particle-positive population was calculated as described previously. Error 
shown is ±SD (N=6). The # represents p<0.05 vs the IV dose. 
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Figure 3.14 Distribution of cell-associated particles as a function of route of administration 
Using the same dataset generated in 3.12, the percentage of cell-associated particles contained within 
each sub-population, as measured by fluorescence, as a function of route of administration. Error shown 
is ±SD (N=6). 
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Figure 3.15 Two photon imaging of normal mouse dermis 
Tumor-bearing nude mice were injected with 40mg/kg 80 x 320 nm particles. Images were taken before 
and 18 hours post-injection. Secondary harmonics show the collagen fibers with Dylight 488 representing 
the particle fluorescence. Images are from a 25x objective, with a maximum intensity projection image (all 
images in the z-stack are shown as a single 2D image), and scale bars representing 50µm. 
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Figure 3.16 Two photon imaging of tumors 
Secondary harmonics are the collagen fibers, Dylight 488 is particle fluorescence, and tdTomato is 
expressed by the cancer cells. A) Tumors were imaged before, and 10 minutes, 24 hours, and 4 days 
post injection. In B) at 24 hours, 3x zoomed in images of two separate fields of view (top, bottom) show 
particle colocalization with cancer and host cells. Images are collected using a 25x objective. The images 
shown are maximum intensity projection images where all images in a z-stack are shown as a single 2D 
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image, with a 3µm space between each slice. The scale bars represent 50µm. These are representative 
images from a small cohort (N = 2-3) animals using the same laser power and instrument settings 
between animals and time points.  
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CHAPTER IV: CONCLUSIONS AND FUTURE DIRECTIONS 
 
 In the present collection of studies, we sought to elucidate the cellular distribution of 80 x 320 nm 
PRINT hydrogel particles within the tumor itself. These data show that certain cell types such as 
macrophages preferentially associate with more particles than all other cell types and contain the highest 
percentage of particle-positive cells. In contrast, cancer cells represent 90% of all cells within the tumor 
and have a small fraction of cells associating with particles. Though only a small fraction of cancer cells 
are particle-positive cancer cells are the large majority of particle-positive cells. Moreover, dose-
dependent association is seen at lower doses of particles (12.5, 40 mg/kg), but at higher doses 
(125mg/kg) the association shows a dose-independent plateau. Coincidentally, the amount of particles in 
each particle-positive macrophage increases dramatically. This suggests that as the cancer cells become 
saturated in their ability to associate with particles, macrophages increasingly become a sink for particles. 
 Radioactive studies of the whole organ suggest that at these three doses, particle accumulation 
of the tumor stays constant at around 1% of the injected dose. This demonstrates that accumulation in 
the organ is linear. Contrasted with the flow cytometry data, it suggests that the particles are 
accumulating in non-cell compartments such as the extracellular matrix.  
 These data also reveal that smaller particle size enhances the cancer cell association two-fold. 
Whether this is due to the physical ability of the particles to diffuse to other cells or a greater ability of the 
cells to associate with the particles is unclear. Route of administration also seemed to play a significant 
role in particle cell association. Injection of particles intratumorally increased cancer cell association and 
decreased macrophage, neutrophil, and other leukocyte association. Moreover, the cancer cells 
association with particles from the intratumorally injected animals showed a 2-3 fold increase in the mean 
fluorescence intensity, suggesting that the particles per cell was greatly enhanced. This experiment 
suggests that there is some sort of physical barrier such as diffusion between cells or the porosity of the 
blood vessels that is preventing 80 x 320 nm particles from reaching the maximum potential association. 
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 Several questions arise from this research. What percentage of the detected macrophages within 
the tumor are monocytes that have associated with a particle while in blood and come to the tumor to 
differentiate? This is an intriguing question as it may lend credence to the hypothesis that macrophages 
are trafficking particles to the tumor as opposed to particles accumulating there as posited by the EPR 
effect. A similar type of effect has been seen with the blood-brain barrier[1,2]. The addition of multi-color 
flow cytometry to this set of experiments could begin to answer fundamental questions about the 
trafficking of nanoparticles to specific sites, be it brain or tumor. Specifically, by fluorescently labeling the 
macrophages or using GFP-expressing macrophages, and incubating with fluorescently labeled 
nanoparticles (fluorophore A), this would allow for determination of not only whether those nanoparticles 
are being delivered to cells, but also a rough estimation of just how much of the nanoparticles are left in 
the macrophages itself as it would be possible to run a sample of the loaded macrophages when 
analyzing the experimental samples. Moreover, using the labeled/GFP-expressing macrophages would 
also quantify of the fraction of macrophages present in the tissue that are the injected/labeled ones, 
providing information on the effectiveness of your delivery strategy. Additionally, should any ofhter cells in 
the body take up those fluorescently labeled particles, it would suggest that the macrophages are either 
making physical contact or ejecting the nanoparticles from the cell, indicating successful delivery of the 
nanoparticles.  
 Furthermore, if one were to intravenously inject a second, differently fluorescently labeled 
nanoparticle (fluorophore B), one could compare the ratio of the fluorophore A to fluorophore B and 
determine the efficiency of intravenously injected nanoparticles as compared with macrophage-delivered 
particles.  
 Additional questions include what effect does particle number have on cell association? Would 
greater numbers of smaller particles be better for delivery than lesser amounts of larger particles? This is 
a highly difficult question to discern as any changes in particle numbers is confounded by particle size or 
physical amounts. And given downstream applications would be focused on efficacy and treatment, this 
leads to fundamental questions about particle-mediated delivery. Would it be better to deliver more, 
smaller amounts of cargo contained in particles or minimal, large amounts of cargo contained in large 
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particles? These questions directly impact nanoparticle efficacy and pharmacokinetics, which can be 
directly related to nanoparticle drug loading and dosing schedule[3,4]  
 One intriguing question strikes at the heart of flow cytometry assays using nanoparticles: what 
particle fluorescence is needed to discriminate between the cell that is without particles and the cell that 
contains a single particle? i.e. what’s the signal to noise or how many particles does it take to be 
considered particle-positive? Clearly in this data, the particle fluorescence is unable to discriminate to 
such an extent, but would play a large influence in accurate quantitation of the amount of association. 
 Obviously, there is still much work to be done. I have only used one type of enzymatic method in 
order to dissociate my tumors. There are a variety of enzymatic and physical methods with which to 
accomplish the same task. It may be interesting to compare and contrast the resulting cell populations 
and association as a function of the method used.  
 There are many other factors of particles not included in these studies which would be of interest 
and benefit. A basic particle characteristic like shape may reveal interesting observations. Certainly 
Mitragotri and other others have shown shape to impact the clearance and circulation time of particles[5-
12], however, specific and controlled insight into how that may affect delivery and interact with cells is 
less well understood. Other characteristics like charge, composition, or a broader range of sizes may also 
reveal important biological insights, particularly size. In comparing size it is important to note the role that 
the inherent brightness of the particle will play in detection of the particles by fluorescence. It is common 
to dope the particle by wt% and for different sizes, this gives a different physical amount of fluorophore 
per particle. More careful analysis of this parameter may be required to cleanly test nanoparticle 
hypothesis comparing size using fluorescence. Though it would be difficult to control for particle 
brightness, for a given size, determining the dose at which cell association reaches a maximum and 
whether that maximum changes in comparison to other sizes may give particular fundamental biological 
insight into tumor pore size and diffusability of the particles. This kind of sub-organ cellular analysis may 
also help elucidate whether the prevailing hypothesis about targeted particles is correct. The prevailing 
wisdom is that targeted particles only assist in having cells endocytose particles as opposed to 
accumulating within the organ. Flow cytometry would be able to more directly answer this question in 
vivo. In addition, if something fluorescent and detectable by another sensitive method (i.e. quantum dot 
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loaded particles or fluorophore + drug loaded particles) were used, it may be possible to flow sort the 
particle-positive cells from each cell type and then directly quantify the amount of particle per cell using 
the cargo as a surrogate measure. Though it would be nearly impossible to calculate a percent injected 
dose due to not knowing the maximal number of cells in a tumor, this method would allow for a direct 
quantitative comparison of amount of particles per cell. Alternatively, if the particles were large enough, it 
would be possible to simply run a volume of particles directly on the flow cytometry and quantify the 
average fluorescence. In this way, a particle number and average fluorescence could be determined with 
mass being constant. The DeSimone lab has had difficulty analyzing individual 80 x 320 nm particles on a 
flow cytometry(data not shown), but it may be possible for larger particles. The less attractive alternative 
would be flow sort and calculate the amount of particles per cell using a standard curve of particles spiked 
into cells from an uninjected animal. This approach may be labor-intensive, but would be the only way to 
determine how much particles were in contained in each cell for smaller, unloaded particles. 
 It may also be beneficial to extend all this approach to other models, especially to answer more 
fundamental questions about the EPR effect and nanoparticle delivery. One experiment that was 
conducted was to examine what the effect of circulation time on particle association would be. Circulation 
time is presumed to influence the EPR effect and thereby accumulation within tumors. Liposomal 
encapsulated Clodronate (ClodrosomeTM) has been previously found to selectively kill circulating 
macrophages, thereby creating long-circulating nanoparticles[13-16]. For this experiment, Clodronate was 
injected into the peritoneum daily for three days before administering particles. Interestingly, when 
ClodrosomeTM was administered, the percentage of cells associating with particles decreased (data not 
shown). The most likely explanation is that the cancer cells that normally take up particles also took up 
the ClodrosomeTM and subsequently died. Optimization of a dosing protocol may allow this experiment to 
be successful. Alternatively, dosing anti-monocyte antibodies or siRNA targeted natural uptake receptors 
present on their surface, though expensive, may also help answer this question. 
 Cellular level analysis may be beneficial to understanding where and how to best control the 
application of nanomedicine for the treatment of solid tumors. Our data show a distinct profile of the 
distribution of particles within an organ. It is hoped that these data will provide a basic understanding that 
will enhance delivery of therapeutic-loaded particles to obtain a therapeutic effect. Furthermore, this 
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approach can serve as a template for a standard type of analysis performed by other nanomedicine 
scientists. One day, regular clinical use of nanomedicines may be standard practice, but ensuring a solid 
grasp of the fundamentals will be key. 
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